<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004079.pub2" GROUP_ID="COLOCA" ID="342600112621314278" MERGED_FROM="" MODIFIED="2008-08-05 11:51:06 +0200" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-08-05 11:45:30 +0200" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="039" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-08-05 11:51:06 +0200" MODIFIED_BY="Henning Keinke Andersen">
<TITLE>Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas</TITLE>
<CONTACT>
<PERSON ID="12804" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tracey</FIRST_NAME>
<MIDDLE_INITIALS>K.</MIDDLE_INITIALS>
<LAST_NAME>Asano</LAST_NAME>
<SUFFIX/>
<POSITION>Resident</POSITION>
<EMAIL_1>tasano@mtsinai.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Surgery</DEPARTMENT>
<ORGANISATION>University of Toronto</ORGANISATION>
<ADDRESS_1>c/o Dr. Robin McLeod</ADDRESS_1>
<ADDRESS_2>600 University Ave Suite 449</ADDRESS_2>
<CITY>Toronto</CITY>
<ZIP>M5G 1X5</ZIP>
<REGION>ONT</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>416-586-4800 ext: 6667</PHONE_1>
<PHONE_2/>
<FAX_1>416-586-5932</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS>
<PERSON ID="12804" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tracey</FIRST_NAME>
<MIDDLE_INITIALS>K.</MIDDLE_INITIALS>
<LAST_NAME>Asano</LAST_NAME>
<SUFFIX/>
<POSITION>Resident</POSITION>
<EMAIL_1>tasano@mtsinai.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Surgery</DEPARTMENT>
<ORGANISATION>University of Toronto</ORGANISATION>
<ADDRESS_1>c/o Dr. Robin McLeod</ADDRESS_1>
<ADDRESS_2>600 University Ave Suite 449</ADDRESS_2>
<CITY>Toronto</CITY>
<ZIP>M5G 1X5</ZIP>
<REGION>ONT</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>416-586-4800 ext: 6667</PHONE_1>
<PHONE_2/>
<FAX_1>416-586-5932</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5382" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Robin</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>McLeod</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>rmcleod@mtsinai.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of General Surgery</DEPARTMENT>
<ORGANISATION>Mount Sinai Hospital</ORGANISATION>
<ADDRESS_1>449-600 University Avenue</ADDRESS_1>
<ADDRESS_2>Suite 451</ADDRESS_2>
<CITY>Toronto</CITY>
<ZIP>M5G 1X5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 416 586 8347</PHONE_1>
<PHONE_2/>
<FAX_1>+1 416 586 8644</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-08-05 11:51:06 +0200" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Minor update: 12/02/04&lt;/p&gt;" NOTES_MODIFIED="2008-08-05 11:45:30 +0200" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="17" MONTH="11" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="11" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="9" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2004"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="5" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="17" MONTH="11" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Mount Sinai Hospital</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Toronto, Department of Surgery</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Dr. TK Asano - Research Fellow of the National Cancer Institute of Canada with funds provided by the Canadian Cancer Society</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Colorectal (bowel) cancer is common worldwide but is especially prevalent in industrialised countries. Genes, diet and lifestyle all seem to be important in the development of bowel cancer.</TITLE>
<SUMMARY_BODY>
<P>Experimental animals studies and observational studies have suggested that nonsteroidal anti-inflammatory drugs and aspirin may reduce the development of colorectal cancer and recurrence of adenomas in patients with familial adenomatous polyposis (FAP). </P>
<P>The review found some evidence to support the effectiveness of aspirin for reducing the risk of recurrent sporadic colorectal adenomas. Further, there is evidence from short-term studies to support regression, but not elimination or prevention of colorectal adenomas in FAP with NSAIDs. <BR/>The review suggests more research on the long-term role of NSAIDs.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>There is evidence from experimental animals studies, prospective and retrospective observational studies that nonsteroidal anti-inflammatory drugs (NSAIDS) may reduce the development of sporadic colorectal adenomas (CRAs) and cancer (CRC) and may induce the regression of adenomas in familial adenomatous polyposis (FAP).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To conduct a systematic review to determine the effect of NSAIDS for the prevention or regression of CRAs and CRC. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Randomized controlled trials (RCTs) up to September 2003 were identified.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>NSAIDS and aspirin (ASA) were the interventions. The primary outcomes were the number of subjects with at least one CRA, the change in polyp burden, and CRC. The secondary outcome was adverse events. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently extracted data and assessed trial quality. Dichotomous outcomes were reported as relative risks (RR) with 95% confidence intervals (CI). The data were combined with the random effects model if clinically and statistically reasonable.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria. The interventions included sulindac, celecoxib, or aspirin (ASA). From the combined results of three trials, significantly fewer subjects in the low dose ASA group developed recurrent sporadic CRAs [RR 0.77 (95% CI 0.61, 0.96), (NNT 12.5 (95% CI 7.7, 25)] after one to three years. In another three trials, phenotypic FAP subjects that received sulindac or celecoxib had a greater proportional reduction (range: 11.9% to 44%) in the number of CRAs compared to those in the control group (range: 4.5% to 10%). There was no significant difference for the outcomes of CRC or adverse events in any of the trials.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There was evidence from three pooled RCTs that ASA significantly reduces the recurrence of sporadic adenomatous polyps after one to three years. There is evidence from short-term studies to support regression, but not elimination or prevention of CRAs in FAP.<BR/> </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Colorectal cancer (CRC) is a major cause of morbidity and mortality in industrialized countries. It is the third most common cause of cancer-related deaths in North America (<LINK REF="REF-CCS-2002" TYPE="REFERENCE">CCS 2002</LINK>, <LINK REF="REF-ACS-2003" TYPE="REFERENCE">ACS 2003</LINK>). In most cases, CRC develops from a precursor lesion that becomes cancerous through a multi-step adenoma-carcinoma sequence (<LINK REF="REF-Hill-1978" TYPE="REFERENCE">Hill 1978</LINK>). Routine CRC screening has been shown to be effective in reducing cancer related mortality by the detection and removal of precancerous adenomatous polyps or by the early detection of cancer (<LINK REF="REF-Winawer-1993" TYPE="REFERENCE">Winawer 1993</LINK>, <LINK REF="REF-Mandel-1993" TYPE="REFERENCE">Mandel 1993</LINK>, <LINK REF="REF-Kronborg-1996" TYPE="REFERENCE">Kronborg 1996</LINK>, <LINK REF="REF-Hardcastle-1996" TYPE="REFERENCE">Hardcastle 1996</LINK>, <LINK REF="REF-Kewenter-1988" TYPE="REFERENCE">Kewenter 1988</LINK>, <LINK REF="REF-Newcomb-1992" TYPE="REFERENCE">Newcomb 1992</LINK>; <LINK REF="REF-Trends-2001" TYPE="REFERENCE">Trends 2001</LINK>). Despite the benefits, there is an inadequate awareness and utilization of CRC screening (<LINK REF="REF-MMWR-2001" TYPE="REFERENCE">MMWR 2001</LINK>, <LINK REF="REF-Vernon-1997" TYPE="REFERENCE">Vernon 1997</LINK>). Therefore alternate means of preventing CRC are desirable and have been an expanding focus in cancer research.</P>
<P>Chemoprevention is a concept coined by Michael B. Sporn in 1976, that describes the use of a pharmacologic or natural agents for the purpose of "prevention of the initiation, promotion and progression of carcinogenesis" (<LINK REF="REF-Theisen-2001" TYPE="REFERENCE">Theisen 2001</LINK>). There is a substantial amount of experimental and observational data that support the hypothesis that nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin (ASA) (<LINK REF="REF-Sturmer-1998" TYPE="REFERENCE">Sturmer 1998</LINK>), have chemopreventive properties for colorectal adenomas (CRAs) and cancer. One mechanism proposed for the preventive effects of NSAIDs is through the inhibition of cyclooxygenase-2 (<LINK REF="REF-Dannenberg-1999" TYPE="REFERENCE">Dannenberg 1999</LINK>). Cyclooxygenase is an enzyme that catalyzes the reaction that produces prostaglandins from arachidonic acid. There are two isomers of cyclooxygenase. Cyclooxygenase-1 is expressed in most tissues and produces prostaglandins that mediate normal physiologic functions. Cyclooxygenase-2 is undetectable in most normal tissues but is elevated in CRAs and cancers. There is experimental evidence in animal models that demonstrates the potential contribution of cyclooxygenase-2 to colorectal tumour growth and development, through its influence on apoptosis, cell migration, attachment, invasion and angiogenesis (<LINK REF="REF-Dannenberg-1999" TYPE="REFERENCE">Dannenberg 1999</LINK>, <LINK REF="REF-Gupta-2000" TYPE="REFERENCE">Gupta 2000</LINK>). Potential cyclooyxengase independent mechanisms have also been examined (<LINK REF="REF-Gupta-2000" TYPE="REFERENCE">Gupta 2000</LINK>). Therefore it is biologically plausible that both nonselective and selective cyclooxygenase-2 inhibitors could function as chemopreventive agents, but the selective NSAIDs cause significantly fewer serious gastrointestinal adverse effects (<LINK REF="REF-Fitzgerald-2001" TYPE="REFERENCE">Fitzgerald 2001</LINK>). There is evidence from retrospective and prospective observational studies that NSAIDs, the majority assessing ASA, may reduce the development of sporadic CRAs and CRC (<LINK REF="REF-Turner-1993" TYPE="REFERENCE">Turner 1993</LINK>, <LINK REF="REF-Paganini_x002d_Hill-1994" TYPE="REFERENCE">Paganini-Hill 1994</LINK>, <LINK REF="REF-Arber-2000" TYPE="REFERENCE">Arber 2000</LINK>, <LINK REF="REF-Vainio-1997" TYPE="REFERENCE">Vainio 1997</LINK>). There is also observational evidence that nonaspirin NSAIDs may be effective for reducing the number and size of CRAs in the hereditary CRC syndrome, familial adenomatous polyposis (FAP) (<LINK REF="REF-Hawk-1999" TYPE="REFERENCE">Hawk 1999</LINK>).</P>
<P>We have conducted a systematic review of the available evidence from randomized controlled trials that assess the influence of NSAIDs, including ASA, on the outcome of CRAs or CRC.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The primary objectives of this systematic review were to assess the effect of NSAIDs on the incidence or recurrence of CRAs and on the incidence of CRC. A secondary objective was to identify adverse events. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We included all randomized controlled trials (RCTs) that compare NSAIDs to a control.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants from the general population as well as individuals that have the diagnosis of FAP were included in this review. Subjects were included regardless of their personal history of adenomatous polyps or intact colon status. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Studies included in this review have an intervention of a NSAID. This included nonselective and selective cyclooxygenase-2 inhibitors and aspirin. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The outcome of CRAs or CRC had to be confirmed pathologically. <BR/>At least one of the primary outcomes have been reported in order for a study to be included.</P>
<P>Primary outcomes:<BR/>Number of subjects with <BR/>1. at least one adenoma<BR/>2. more than one adenoma<BR/>3. at least one adenoma that is 1 cm or greater<BR/>4. at least one pathologic diagnosis of a tubulovillous or villous adenoma <BR/>5. the new diagnosis of CRC <BR/>or<BR/>6. % change in polyp burden ("polyp burden" to be defined for each trial)<BR/>7. Change in polyp burden: Better/Worse/Same</P>
<P>Secondary outcome:<BR/>Number of subjects that report:<BR/>1. an adverse event<BR/>2. a serious adverse event (Common Toxicity Criteria Grade 3 or 4) (<LINK REF="REF-CTEP-1998" TYPE="REFERENCE">CTEP 1998</LINK>)</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>Randomized controlled trials were identified from Medline (1966-September 2003), Premedline (September 2003), Embase (1980-2003 Week 43), and the Cochrane Controlled Controlled Trials Register (Cochrane Library 2003 issue 3). MeSH headings were included: randomized controlled trial, controlled clinical trial, random allocation, clinical trial, human, adenomatous polyps, adenomas, polyps, colorectal, colonic, rectal, prevention, chemoprevention, nonsteroidal anti-inflammatory, cyclooxygenase inhibitor, aspirin, neoplasms, and cancer. </P>
<P>No language restriction was specified. <BR/>The references from published studies and journal references were handsearched. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>There were two reviewers (TKA, RSM). The identified studies were screened by the reviewers (TKA, RSM) in order to identify articles eligible for inclusion into the review (see Criteria for considering studies for this review). The list of included studies were reviewed by a content expert to ensure that all relevant studies were included (Dr. J. Baron).</P>
<P>The quality of the included trials were evaluated independently by the two reviewers. Selection, performance, detection and attrition bias were detected from the following questions:<BR/>1) Concealment of allocation?<BR/>2) Blinding of intervention?<BR/>3) Intention-to-treat analysis?<BR/>4) Blinding of outcome measurement?<BR/>5) Complete follow-up?</P>
<P>Questions 1-4 were answered as Yes, No, or Unclear. Answers to Question 5 were described as a percentage of complete follow-up. Complete follow-up of at least 85% was considered to be adequate in order to minimize the risk of attrition bias. Clarification from the primary author was sought if the published data provided inadequate information for the review. From the quality assessment of the trials the potential risk of bias was summarized into three categories according to the Cochrane handbook (<LINK REF="REF-Clarke-2003" TYPE="REFERENCE">Clarke 2003</LINK>):</P>
<P> Risk of Bias Interpretation Relationships to individual criteria</P>
<P> A. Low risk of bias Plausible bias unlikely to All of the criteria met: <BR/> seriously alter the results - "Yes" to Questions 1-3<BR/> - complete follow-up &gt;=85%<BR/> B. Moderate risk of bias Plausible bias that raises One or more criteria partly met: <BR/> some doubt about the results - "No" or "Unclear" to one of <BR/> Questions 2 or 3<BR/> or<BR/> - complete follow-up 75-84%<BR/> C. High risk of bias Plausible bias that seriously One or more criteria not met: <BR/> weakens confidence in the - "No" or "Unclear" to <BR/> results Question 1<BR/> or<BR/> - Two of the following: <BR/> "No" or "Unclear" to <BR/> Questions 2 or 3<BR/> or complete follow-up &lt;85%</P>
<P>The data from the included studies were abstracted independently by the two reviewers. Discrepancies were resolved by consensus.</P>
<P>Statistical analyses: For the outcomes that were discrete and numerical, the relative risk (RR) and risk difference (RD) was reported with 95% confidence intervals (CI). If the RD is statistically significant, the number needed to treat (NNT) or the number needed to harm (NNH) was calculated. Statistical heterogeneity was assessed using the chi-square Q-test. The studies were assessed clinically and methodologically to assess if it was reasonable to consider combining the data. If so, the more conservative random effects model was used to account for small clinical and methodologic variations between very similar high quality trials. Data from studies that were found to be at a high risk of bias from the quality assessment or were found to be statistically significantly heterogeneous were not combined. Instead, futher investigation would be undertaken to identify factors that could potentially explain the heterogeneity. An example of a potential factor is if the mean age of the subjects varied significantly between studies. A sensitivity analysis would then be conducted if data from trials were believed to be clinically appropriate to combine but involved studies that were at a high risk of bias from the quality assessment or were statistically heterogeneous. In this situation, the data from all of the studies would be combined and compared to the results obtained from the pooling of the subset of studies that were at low or moderate of bias. The primary outcomes for the secondary prevention of FAP that were reported as continuous or ordinal will be reported descriptively in the additional tables section. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Details of the studies are listed in the Table of Included Studies.<BR/>Study Participants:<BR/>Nine studies with a total of 24,143 subjects met the inclusion criteria. In general, the aim of primary prevention trials is disease prevention in otherwise healthy individuals. Therefore the primary prevention trials included in this review attempted to reduce the development of CRAs or CRC in individuals without a known history of either. Whereas in the secondary prevention trials, the objective was to reduce the recurrence or induce the regression of CRAs in individuals that have a history of CRAs or CRC. For the five trials that included population based or average risk subjects; one primary prevention trial recruited 22,071 male physicians for 5 years (<LINK REF="STD-Gann-1993" TYPE="STUDY">Gann 1993</LINK>), three secondary prevention trials recruited 2,028 subjects had sporadic colorectal adenomas that were removed endoscopically with an intervention for 1 to 3 years (<LINK REF="STD-Baron-2003" TYPE="STUDY">Baron 2003</LINK>; <LINK REF="STD-Sandler-2003" TYPE="STUDY">Sandler 2003</LINK>; <LINK REF="STD-Benamouzig-2003" TYPE="STUDY">Benamouzig 2003</LINK>), and one small secondary prevention trial included 44 subjects that had polyps diagnosed on routine CRC screening with flexible sigmoidoscopies that were left in situ for 4 months (<LINK REF="STD-Ladenheim-1995" TYPE="STUDY">Ladenheim 1995</LINK>). For the four trials that included subjects with FAP, there was one primary prevention trial that included 41 subjects for 4 years that were genotypically FAP (<LINK REF="STD-Giardiello-2002" TYPE="STUDY">Giardiello 2002</LINK>), but were phenotypically normal and three secondary prevention trials that recruited a total of 109 subjects that had phenotypic FAP for an intervention between 4 to 9 months (<LINK REF="STD-Steinbach-2000" TYPE="STUDY">Steinbach 2000</LINK>; <LINK REF="STD-Giardiello-1993" TYPE="STUDY">Giardiello 1993</LINK>,<LINK REF="STD-Labayle-1991" TYPE="STUDY">Labayle 1991</LINK>). <BR/>Types of interventions:<BR/>The trials that included general population subjects generally included low dose ASA as the intervention (<LINK REF="STD-Gann-1993" TYPE="STUDY">Gann 1993</LINK>; <LINK REF="STD-Baron-2003" TYPE="STUDY">Baron 2003</LINK>; <LINK REF="STD-Sandler-2003" TYPE="STUDY">Sandler 2003</LINK>) except one trial that included sulindac (<LINK REF="STD-Labayle-1991" TYPE="STUDY">Labayle 1991</LINK>). The trials that included subjects with FAP included sulindac or celecoxib as an intervention.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The quality assessment for each study is listed in the Table of Included Studies.<BR/>Overall the nine included studies were of high methodologic quality. Eight of the included studies were determined to be at low risk for bias as they met all criteria of the quality assessment with at least 90% complete follow-up (<LINK REF="STD-Baron-2003" TYPE="STUDY">Baron 2003</LINK>; <LINK REF="STD-Gann-1993" TYPE="STUDY">Gann 1993</LINK>; <LINK REF="STD-Giardiello-1993" TYPE="STUDY">Giardiello 1993</LINK>; <LINK REF="STD-Giardiello-2002" TYPE="STUDY">Giardiello 2002</LINK>; <LINK REF="STD-Labayle-1991" TYPE="STUDY">Labayle 1991</LINK>; <LINK REF="STD-Ladenheim-1995" TYPE="STUDY">Ladenheim 1995</LINK>; <LINK REF="STD-Steinbach-2000" TYPE="STUDY">Steinbach 2000</LINK>; <LINK REF="STD-Benamouzig-2003" TYPE="STUDY">Benamouzig 2003</LINK>). Only one trial met four out of the five quality assessment criteria, because it attained an 81% complete follow-up and as a result was considered to be at moderate risk for bias (<LINK REF="STD-Sandler-2003" TYPE="STUDY">Sandler 2003</LINK>). </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>From the electronic search, thirteen potentially relevant references were identified and four references were identified through handsearching. One was excluded because this trial assessed only the effect of nonsteroidal-inflammatory drugs (NSAIDs) on upper gastrointestinal polyps in familial adenomatous polyposis (FAP) subjects (<LINK REF="REF-Seow_x002d_Choen-1996" TYPE="REFERENCE">Seow-Choen 1996</LINK>). As a result the manuscripts for sixteen references were retrieved and of these, seven were excluded. One trial was excluded because randomization was conducted for patients with advanced duodenal polyposis and the patients with rectal polyps were nonrandomized and were analyzed as a subgroup (<LINK REF="STD-Nugent-1993" TYPE="STUDY">Nugent 1993</LINK>), four trials were ongoing (<LINK REF="STD-Women_x0027_s-Health-Study" TYPE="STUDY">Women's Health Study</LINK>; <LINK REF="STD-CAPP1" TYPE="STUDY">CAPP1</LINK>; <LINK REF="STD-WHI-1998" TYPE="STUDY">WHI 1998</LINK>; <LINK REF="STD-CAPP2" TYPE="STUDY">CAPP2</LINK>), and two manuscripts related to trials that were already identified (<LINK REF="STD-APACC-2001" TYPE="STUDY">APACC 2001</LINK>; <LINK REF="REF-MD-Health-1988" TYPE="REFERENCE">MD Health 1988</LINK>). The trial characteristics are listed in the TABLE OF INCLUDED STUDIES. It was often not possible to combine the data because the included trials differed significantly by the type of participants (ie: general population versus FAP patients), the study design (ie: primary prevention trials where the outcome were identified by subject self-report versus secondary prevention where the primary outcomes were identified by endoscopy). Thus overall, a systematic review was conducted and the data were combined with meta-analytic techniques when appropriate. The raw and summarized outcomes for the individual studies are listed in the ADDITIONAL TABLES and FIGURES sections.</P>
<P>Population Based Subjects<BR/>Population based subjects were subjects considered to be from the general population, or "average" risk subjects for CRAs or cancer. There were four trials comparing ASA to placebo. In all four trials, there was a trend in favour of ASA however the difference reached statistical significance in only one trial (<LINK REF="STD-Sandler-2003" TYPE="STUDY">Sandler 2003</LINK>). One trial was a population based primary prevention study in which male physicians received 325mg of ASA on alternate days and the outcome was the incidence of self-reported CRAs or CRC (<LINK REF="STD-Gann-1993" TYPE="STUDY">Gann 1993</LINK>). No statistically significant reduction for the incidence of sporadic CRAs was noted after five years [RR 0.87 (95% CI 0.68,1.10)]. Results were pooled from three secondary prevention trials as the outcomes were not statistically significantly heterogeneous (p=0.11) and the study designs were similar. However a random effects model was used because the lengths of ASA intervention varied from 1 to 3 years and unlike the other two trials, one included subjects with a history of CRC (<LINK REF="STD-Sandler-2003" TYPE="STUDY">Sandler 2003</LINK>). </P>
<P>When the results were combined there was a statistically significant reduction in the recurrence of sporadic CRAs with an intervention of low-dose ASA for one to three years [RR 0.77 (95% CI 0.61, 0.96), RD -0.08 (95% CI -0.13,-0.04), NNT 12.5 (95% CI 7.7, 25)] (<LINK REF="STD-Baron-2003" TYPE="STUDY">Baron 2003</LINK>; <LINK REF="STD-Benamouzig-2003" TYPE="STUDY">Benamouzig 2003</LINK>; <LINK REF="STD-Sandler-2003" TYPE="STUDY">Sandler 2003</LINK>) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). <BR/>In one of these secondary prevention trials, 517 subjects with previous CRC were randomized to ASA 325 mg daily or placebo (<LINK REF="STD-Sandler-2003" TYPE="STUDY">Sandler 2003</LINK>). This trial was terminated early because there was a statistically significant reduction in the recurrence of sporadic CRAs in the intervention group after a median of 12.8 months after randomization [RR 0.61 (95% CI 0.44,0.86), RD -0.11 (95% CI -0.18,-0.03), NNT 9 (95% CI 6, 33)] (<LINK REF="STD-Sandler-2003" TYPE="STUDY">Sandler 2003</LINK>). <BR/>The other two trials were similar in design, except subjects with CRC were excluded and individually there was no statistically significant reduction in the recurrence of CRAs (<LINK REF="STD-Baron-2003" TYPE="STUDY">Baron 2003</LINK>; <LINK REF="STD-Benamouzig-2003" TYPE="STUDY">Benamouzig 2003</LINK>). However, in a subgroup receiving 81mg of ASA daily there was a significant reduction in recurrent CRAs [RR 0.81 (95% CI 0.69,0.96)] that was not observed in a subgroup receiving 325mg daily [RR 0.96 (95% CI 0.81-1.13)] by Baron and colleagues however the opposite nonstatistically significant trend was found by Benzamouzig and colleagues [25% rates of recurrence with 300mg of lysine acetylsalicylate and 35% recurrence with 160 mg (p=0.23)]. <BR/>There was a fifth small secondary prevention trial where no significant regression of identified small sporadic CRAs was observed after four months of sulindac compared to a placebo group [RR 1.67 (95% CI 0.45,6.14)] (<LINK REF="STD-Ladenheim-1995" TYPE="STUDY">Ladenheim 1995</LINK>). </P>
<P>Polyps in Familial Adenomatous Polyposis <BR/>There were four RCTs that included subjects with FAP. There was one primary prevention trial that recruited subjects with a disease-causing mutation of the adenomatous polyposis coli gene but no phenotypic expression of FAP, and after four years of intervention with sulindac had no statistically significant difference in the incidence of CRAs compared to a control [RR 0.78 (95% CI 0.41,1.147)] (<LINK REF="STD-Giardiello-2002" TYPE="STUDY">Giardiello 2002</LINK>). Three trials were secondary prevention RCTs with phenotypic FAP subjects who received sulindac or celecoxib for four to nine months (<LINK REF="STD-Giardiello-1993" TYPE="STUDY">Giardiello 1993</LINK>; <LINK REF="STD-Labayle-1991" TYPE="STUDY">Labayle 1991</LINK>; <LINK REF="STD-Steinbach-2000" TYPE="STUDY">Steinbach 2000</LINK>). Investigators attempted to standardize outcome assessment within their own trial, but because of the numerous polyps, standardization between trials was not possible and therefore the results have been reported descriptively. There was a greater proportional reduction (range: 11.9% to 44%) in the number of colorectal adenomas in the intervention groups compared to those in the control group (range: 4.5% to 10%) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). </P>
<P>Other Outcomes<BR/>There was no statistically significant difference in the outcomes of higher risk CRAs (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), CRC (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) or adverse events (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) in any of the trials. <BR/> </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>DISCUSSION<BR/>From nine high quality published RCTs, there is some evidence for the effectiveness of NSAIDs and ASA in the prevention of CRAs for the average risk and individuals with FAP. From the combined results of three trials, low dose ASA was found to statistically significantly reduce the rates of recurrent sporadic adenomas after one to three years (<LINK REF="STD-Baron-2003" TYPE="STUDY">Baron 2003</LINK>; <LINK REF="STD-Benamouzig-2003" TYPE="STUDY">Benamouzig 2003</LINK>; <LINK REF="STD-Sandler-2003" TYPE="STUDY">Sandler 2003</LINK>). There is no apparent biologic explanation for the significant benefit received by the subgroup from the lower dose of 81mg of aspirin that was not found in the subgroup that received 325mg daily (<LINK REF="STD-Baron-2003" TYPE="STUDY">Baron 2003</LINK>). Perhaps this may have been a chance finding. </P>
<P>Additionally, there are limitations to these trials. First, in the majority of the trials the end-point was a surrogate biomarker and not the clinically more relevant end-point of CRC. However CRAs are the most suitable intermediate biomarker as they are precursors of CRC, are clinically identifiable and resectable (<LINK REF="REF-Winawer-1993" TYPE="REFERENCE">Winawer 1993</LINK>). Clinical support for this include results from a retrospective review of Mayo Clinic records for 226 patients with colonic polyps at least 10mm in diameter that elected for periodic radiographic follow-up instead of excision between January 1965 and December 1970 (<LINK REF="REF-Stryker-1987" TYPE="REFERENCE">Stryker 1987</LINK>). The cumulative risk for cancer at the polyp site at 5, 10, and 20 years was 2.5%, 8% and 24% respectively. The coloretal outcomes were published from St. Mark's Hospital for 1 618 patients that had at least one rectosigmoid polypectomy with a rigid-sigmoidoscopy who did not undergo surveilance (<LINK REF="REF-Atkin-1992" TYPE="REFERENCE">Atkin 1992</LINK>). The incidence of subsequent rectal cancer was found to be similar to the general population rates if the polyp had been adequately removed, and the risk of subsequent colon cancer was increased for tubulovillous, villous, multiple or large (&gt;=1cm) polyps. Furthermore, primary prevention trials with the incidence of CRC as an endpoint would require prohibitively large sample sizes and a long follow-up period. Despite there being 22,072 men in The Physicians' Health Study a significant decrease in the outcome of CRC was not observed after five years of follow-up (<LINK REF="STD-Gann-1993" TYPE="STUDY">Gann 1993</LINK>). This suggests further caution when interpreting the results. Perhaps the duration of the intervention was too brief and was started too late in order to reduce the incidence CRC. The polyp-cancer sequence is a multi-step process that often has a natural history of 10 to 15 years and a relatively short duration intervention may not interrupt it (<LINK REF="REF-Winawer-1993" TYPE="REFERENCE">Winawer 1993</LINK>). Also, the Physicians' Health Study relied on self-report of CRC and CRAs and may have failed to detect a significant difference because of the low sensitivity of measuring the outcome. Finally, with regard to the FAP trials, assessment of the number of adenomas in the rectum is notoriously inaccurate especially with respect to identifying microadenomas. </P>
<P>Based on these results, further studies are required to clarify the effectiveness of these agents. Many questions remain unanswered, including the identification of the most effective type, dosage or duration of an NSAID intervention. It is also unknown whether these medications are equally effective as primary and secondary chemopreventive agents. There are numerous ongoing studies that may provide some answers. Of these, there are two RCTs that will test the effect of low dose aspirin for recurrent sporadic CRAs. The final four year results of trial by Benamouzig and colleagues will provide more information about optimal dosages of ASA (<LINK REF="STD-Benamouzig-2003" TYPE="STUDY">Benamouzig 2003</LINK>) and the other is the ukCAP trial which plans to recruit 1300 subjects with a 2x2 factorial intervention that includes a 300mg ASA intervention for 4 years (<LINK REF="REF-ukcccr-2002" TYPE="REFERENCE">ukcccr 2002</LINK>). Also, one trial includes an aspirin and/or resistant starch intervention for the prevention of CRAs for hereditary nonpolyposis CRC gene carriers (<LINK REF="STD-CAPP2" TYPE="STUDY">CAPP2</LINK>), and the Women's Health Study which is a eight to ten year primary prevention trial that includes a 100mg aspirin arm for the prevention of cardiovascular disease and site-specific cancer in women (<LINK REF="STD-Women_x0027_s-Health-Study" TYPE="STUDY">Women's Health Study</LINK>). </P>
<P>Although the data from these trials suggest that NSAIDs and ASA can be taken without increased adverse events [RR 0.92 (95% 0.65, 1.32)], the results from these trials may not be generalizable because individuals at higher risk for adverse events were excluded. Also, the four largest studies (<LINK REF="STD-Sandler-2003" TYPE="STUDY">Sandler 2003</LINK>; <LINK REF="STD-Gann-1993" TYPE="STUDY">Gann 1993</LINK>; <LINK REF="STD-Baron-2003" TYPE="STUDY">Baron 2003</LINK>; <LINK REF="STD-Benamouzig-2003" TYPE="STUDY">Benamouzig 2003</LINK>) had a one to three month run-in phase with low dose ASA, therefore individuals that had reduced compliance due to medication intolerance or adverse events would also have been excluded from the trials. Based on results from other trials, it has been estimated that low dose aspirin may cause 2 to 4 major gastrointestinal bleeding episodes and 0 to 2 excess hemorrhagic strokes per 1000 middle-aged persons after five years (<LINK REF="REF-USPTF-2002" TYPE="REFERENCE">USPTF 2002</LINK>). Despite the improved gastrointestinal toxicity profile, recent evidence has suggested that selective cyclooxygenase-2 inhibitors may have a prothrombotic potential and may increase the risk of cardiovascular events(<LINK REF="REF-Mukherjee-2001" TYPE="REFERENCE">Mukherjee 2001</LINK>). Thus, the risks and overall benefits of NSAIDs for individual patients must be weighed.</P>
<P>Finally, an important question that remains unanswered is whether chemopreventive strategies with NSAIDs have a role for individuals at average risk for the development of CRAs or CRC or whether strategies to increase compliance with screening would be more effective. Recently, two analyses concluded that aspirin 325mg daily was not a cost-effective substitute or addition to routine CRC screening due to aspirin-related complication rates (<LINK REF="REF-Suleiman-2001" TYPE="REFERENCE">Suleiman 2001</LINK>; <LINK REF="REF-Ladabaum-2001" TYPE="REFERENCE">Ladabaum 2001</LINK>).</P>
<P>For patients with FAP, short-term regression, but not complete elimination of polyps was noted in three RCTs. There is some supporting evidence from nonrandomized studies that NSAIDS may be effective for long-term regression of polyps in FAP. In a case series, 12 FAP patients with ileorectal anastomoses who received a mean dosage of 158mg daily of sulindac had a reduced polyp burden after a mean of 63.4+/-31.3 months (<LINK REF="REF-Cruz_x002d_Correa-2002" TYPE="REFERENCE">Cruz-Correa 2002</LINK>). It is important to note that rectal cancer, an increase in polyp number and refractory rectal mucosal erosions also occurred in some individuals within this same cohort. As well, there have been other published reports of rectal cancer developing in FAP patients despite sulindac treatment (<LINK REF="REF-Niv-1994" TYPE="REFERENCE">Niv 1994</LINK>; <LINK REF="REF-Thorson-1994" TYPE="REFERENCE">Thorson 1994</LINK>) as well as evidence of sulindac-resistent adenomas (<LINK REF="REF-Keller-2001" TYPE="REFERENCE">Keller 2001</LINK>). There is limited conflicting evidence from randomized controlled trials about the potential role of NSAIDS for the regression of duodenal polyps (<LINK REF="REF-Seow_x002d_Choen-1996" TYPE="REFERENCE">Seow-Choen 1996</LINK>; <LINK REF="STD-Nugent-1993" TYPE="STUDY">Nugent 1993</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is some evidence from the pooled data of three RCTs to support the effectiveness of one to three years of ASA for reducing the risk of recurrent sporadic CRAs. Similarly, there is evidence from short-term studies to support regression, but not elimination or prevention of CRAs in FAP with NSAIDs. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>More evidence from ongoing RCTs is necessary to establish the long-term role of NSAIDs for the prevention of CRAs in addition to currently recommended CRC screening strategies for the average risk population or routine surveillance for post-polypectomy or FAP patients.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are grateful to:<BR/>- Dr. J. Baron for expert assistance regarding completeness of our list of included studies<BR/>- trialists Dr. R. Benamouzig, Dr. J. Baron, L.A. Mott, Dr. IM Lee for responding to requests for information<BR/>- Dr. H.K. Andersen &amp; the Cochrane Colorectal Cancer Group</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>none known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Dr. Tracey Asano <BR/>Literature search and identification of trials for inclusion<BR/>Evaluation of methodologic quality of included trials<BR/>Abstraction of data<BR/>Verifying and entering data into RevMan<BR/>Writing the text of the draft review<BR/>Writing the final manuscript.</P>
<P>Dr. Robin McLeod</P>
<P>Reviewed the results of the literature search to identify trials for inclusion<BR/>Evaluation of methodologic quality of included trials<BR/>Abstraction of data<BR/>Review and substantial editing to the draft review<BR/>Writing the final manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Baron-2003" NAME="Baron 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeowyn-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck, GJ, Bond JH, Byers T. Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F. vanStok RU</AU>
<TI>A randomized trial of aspirin to prevent colorectal adenomas</TI>
<SO>N Engl J Med</SO>
<YR>2003</YR>
<VL>348</VL>
<PG>891-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benamouzig-2003" NAME="Benamouzig 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S</AU>
<TI>Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-yr results of the APACC Trial</TI>
<SO>Gastroeneterology</SO>
<YR>2003</YR>
<VL>125</VL>
<PG>328-336</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gann-1993" NAME="Gann 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH</AU>
<TI>Low-dose aspirin and incidence of colorectal tumors in a randomized trial</TI>
<SO>J Natl Cancer Inst</SO>
<YR>1993</YR>
<VL>85</VL>
<PG>1220-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Steering Committee of the Physicians' Health Group</AU>
<TI>Preliminary report: findings from the aspirin component of the ongoing physicians' health study</TI>
<SO>N Engl J Med</SO>
<YR>1988</YR>
<VL>318</VL>
<PG>262-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giardiello-1993" NAME="Giardiello 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus JA</AU>
<TI>Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis</TI>
<SO>N Engl J Med</SO>
<YR>1993</YR>
<VL>328</VL>
<PG>1313-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giardiello-2002" NAME="Giardiello 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman GE, Hubbard W, Offerhaus JA, Hamilton SR</AU>
<TI>Primary chemoprevention of familial adenomatous polyposis with sulindac</TI>
<SO>N Engl J Med</SO>
<YR>2002</YR>
<VL>346</VL>
<PG>1054-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Labayle-1991" NAME="Labayle 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P</AU>
<TI>Sulindac causes regression of rectal polyps in familial adenomatous polyposis</TI>
<SO>Gastroenterology</SO>
<YR>1991</YR>
<VL>101</VL>
<PG>635-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladenheim-1995" NAME="Ladenheim 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, Omary MB</AU>
<TI>Effect of sulindac on sporadic colonic polyps</TI>
<SO>Gastroenterology</SO>
<YR>1995</YR>
<VL>108</VL>
<PG>1083-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandler-2003" NAME="Sandler 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R</AU>
<TI>A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer</TI>
<SO>N Engl J Med</SO>
<YR>2003</YR>
<VL>348</VL>
<PG>883-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinbach-2000" NAME="Steinbach 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B</AU>
<TI>The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis</TI>
<SO>N Engl J Med</SO>
<YR>2000</YR>
<VL>342</VL>
<PG>1946-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Nugent-1993" NAME="Nugent 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nugent KP, Famer KCR, Spigelman AD, Williams CB, Phillips RKS</AU>
<TI>Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial polyposis</TI>
<SO>Br J Surg</SO>
<YR>1993</YR>
<VL>80</VL>
<PG>1618-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-APACC-2001" NAME="APACC 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benamouzig R, Yoon H, Little J, Martin A, Douturier D, Deyra J, Coste T, Chaussade S</AU>
<TI>APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings</TI>
<SO>Eur J Cancer Prev</SO>
<YR>2001</YR>
<VL>10</VL>
<PG>327-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CAPP1" NAME="CAPP1" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burns J, Chapman PD, Bertario L, Bishop DT, Bulow S, Cummings J, Mathers J, Phillips R, Vasen H</AU>
<TI>The protocol for a European double-blind trial of aspirin and resistant starch in Familial Adenomatous Polyposis: The CAPP Study</TI>
<SO>E J Cancer</SO>
<YR>1995</YR>
<VL>31A</VL>
<PG>1385-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CAPP2" NAME="CAPP2" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burns J, Chapman PD, Mathers J, Bishop DT, Lynch H</AU>
<TI>CAPP2: An international controlled trial of aspirin and resistant starch in carriers of HNPCC</TI>
<SO>J Med Genet</SO>
<YR>1997</YR>
<VL>34[Supplement 1]</VL>
<PG>S53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MDA_x002d_ID_x002d_00109" NAME="MDA-ID-00109" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="COMPUTER_PROGRAM">
<TI>Phase II Randomized study of celecoxib with or without eflornithine for the prevention of colorectal cancer in participants with familial adenomatous polyposis of the colorectum (Summary last modified 04/2002)</TI>
<YR>[Protocol available online. Accessed Nov 2002 at http://www.cancer.gov/search/clinical trials]</YR>
<PB>BioMed Central</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCI_x002d_P00_x002d_0150" NAME="NCI-P00-0150" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="COMPUTER_PROGRAM">
<TI>PhaseIIB randomized study of eflornithine (DFMO) and sulindac in the prevention of colorectal carcinoma in patients with previously resected colorectal adenoma (Summary last modified 07/2002)</TI>
<YR>[Protocol available online. Accessed Nov 2002 at http://www.cancer.gov/search/clinical trials]</YR>
<PB>BioMed Central</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ukCAP" NAME="ukCAP" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="COMPUTER_PROGRAM">
<TI>Randomized study of aspirin and/or folic acid as prevention of recurrent colorectal adenomas in patients who have had colorectal adenomas in patients who have had colorectal adenomas removed (Summary last modified 04/2002)</TI>
<YR>[Protocol available online. (Accessed March 2003 at http://www.controlled-trials.com)]</YR>
<PB>BioMed Central</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WHI-1998" NAME="WHI 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Anonymous. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials. 1998;19(1):61-109.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>1</NO>
<PG>61-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Women_x0027_s-Health-Study" NAME="Women's Health Study" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH</AU>
<TI>B-Carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study</TI>
<SO>J Natl Cancer Inst</SO>
<YR>1999</YR>
<VL>91</VL>
<PG>2102-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-ACS-2003" NAME="ACS 2003" NOTES="&lt;p&gt;Cancer Facts &amp;amp; Figures.  American Cancer Society. [available on-line].: http://www.cancer.org, 2002:&lt;/p&gt;" TYPE="COMPUTER_PROGRAM">
<AU>American Cancer Society</AU>
<TI>Cancer Facts &amp; Figures. [available on-line: accessed on Feb. 2003, http://www.cancer.org]</TI>
<YR>2003</YR>
<PB>American Cancer Society, Inc</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arber-2000" NAME="Arber 2000" NOTES="&lt;p&gt;Arber N. Do NSAIDs prevent colorectal cancer. Canadian Journal of Gastroenterology 2000;14:299-307.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Arber N</AU>
<TI>Do NSAIDs prevent colorectal cancer?</TI>
<SO>Canadian Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>299-307</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atkin-1992" NAME="Atkin 1992" TYPE="JOURNAL_ARTICLE">
<AU>Atkin WS, Morson BC, Cuzick J</AU>
<TI>Long-term risk of colorectal cancer after excision of rectosigmoid adenomas</TI>
<SO>N Engl J Med</SO>
<YR>1992</YR>
<VL>326</VL>
<PG>658-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CCS-2002" NAME="CCS 2002" TYPE="COMPUTER_PROGRAM">
<AU>Canadian Cancer Society</AU>
<TI>Canadian Cancer Statistics. [available on-line: Accessed Feb. 2003, http://www.cancer.ca]</TI>
<YR>2002</YR>
<PB>Canadian Cancer Society</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2003" NAME="Clarke 2003" NOTES="&lt;p&gt;Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1.6 [updated January 2003]. http://www.cochrane.dk/cochrane/handbook/handbook.htm (accessed 12 May 2003). In.&lt;/p&gt;" TYPE="COMPUTER_PROGRAM">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Cochrane Reviewers' Handbook 4.1.6 [updated January 2003]. http://www.cochrane.dk/cochrane/handbook/handbook.htm (accessed 12 May 2003)</TI>
<YR>2003</YR>
<PG>//www.cochrane.dk/cochrane/handbook/handbook.htm (accessed 12 May 2003). In</PG>
<PB>John Wiley and Sons</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cruz_x002d_Correa-2002" NAME="Cruz-Correa 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cruz-Correa M, Hylinda LM, Romans KE, Booker SV, Giardiello FM</AU>
<TI>Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>641-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CTEP-1998" NAME="CTEP 1998" NOTES="&lt;p&gt;cancer therapy evaluation programme&lt;/p&gt;" TYPE="COMPUTER_PROGRAM">
<AU>National Cancer Institute</AU>
<TI>Common toxicity criteria. [available on-line: accessed August 13. 2002, at http//ctep.cancer.gov/reporting.ctc.html]</TI>
<YR>1998</YR>
<PB>National Cancer Institute</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dannenberg-1999" NAME="Dannenberg 1999" TYPE="JOURNAL_ARTICLE">
<AU>Dannenberg AJ, Zakim D</AU>
<TI>Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2</TI>
<SO>Seminars in Oncology</SO>
<YR>1999</YR>
<VL>26</VL>
<PG>499-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzgerald-2001" NAME="Fitzgerald 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald GA, Patrono C</AU>
<TI>The Coxibs, selective inhibitors of cyclooxygenase-2</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<PG>433-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2000" NAME="Gupta 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gupta RA, Dubois RN</AU>
<TI>Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2000</YR>
<VL>910</VL>
<PG>196-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hardcastle-1996" NAME="Hardcastle 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hardcastle JD, Chamberlain JO, Robinson MH, et al</AU>
<TI>Randomised controlled trial of faecal-occult-blood screening for colorectal cancer</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9040</NO>
<PG>1472-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hawk-1999" NAME="Hawk 1999" NOTES="&lt;p&gt;20.Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 1999;86:1731-43.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hawk E, Lubet R, Limburg P</AU>
<TI>Chemoprevention in hereditary colorectal cancer syndromes</TI>
<SO>Cancer</SO>
<YR>1999</YR>
<VL>86</VL>
<PG>1731-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-1978" NAME="Hill 1978" NOTES="&lt;p&gt;Hill MJ, Morson BC, Bussey HJR. Aetiology of adenoma - carcinoma sequence in large bowel. The Lancet 1978;1(8058):245-247.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hill MJ, Morson BC, Bussey HJR</AU>
<TI>Aetiology of adenoma - carcinoma sequence in large bowel</TI>
<SO>The Lancet</SO>
<YR>1978</YR>
<VL>1</VL>
<PG>245-247</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keller-2001" NAME="Keller 2001" TYPE="JOURNAL_ARTICLE">
<AU>Keller JJ, Offerhaus GJA, Drillenburg P, Caspers E, Musler A, Ristimaki A, et al</AU>
<TI>Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis</TI>
<SO>Clinical Cancer Research</SO>
<YR>2001</YR>
<VL>7</VL>
<PG>4000-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kewenter-1988" NAME="Kewenter 1988" NOTES="&lt;p&gt;Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 1988;62(3):645-51.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C</AU>
<TI>Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects</TI>
<SO>Cancer</SO>
<YR>1988</YR>
<VL>62</VL>
<PG>645-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kronborg-1996" NAME="Kronborg 1996" NOTES="&lt;p&gt;Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348(9040):1467-71.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O</AU>
<TI>Randomised study of screening for colorectal cancer with faecal-occult-blood test</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<PG>1467-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ladabaum-2001" NAME="Ladabaum 2001" NOTES="&lt;p&gt;Ladabaum U, Chopra CL, Huanga G, Scheiman JM, Chernew ME, A.M. F. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer:  A cost-effectiveness analysis. Ann Intern Med 2001;135:769-81.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ladabaum U, Chopra CL, Huanga G, Scheiman JM, Chernew ME, A</AU>
<TI>M. F. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: A cost-effectiveness analysis</TI>
<SO>Ann Intern Med</SO>
<YR>2001</YR>
<VL>135</VL>
<PG>769-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mandel-1993" NAME="Mandel 1993" TYPE="JOURNAL_ARTICLE">
<AU>Mandel JS, Bond JH, Church TR</AU>
<TI>Reducing mortality from colorectal cancer by screening for fecal occult blood</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>328</VL>
<NO>19</NO>
<PG>1365-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MD-Health-1988" NAME="MD Health 1988" TYPE="JOURNAL_ARTICLE">
<AU>The Steering Committee of the Physicians' Health Group</AU>
<TI>Preliminary report: findings from the aspirin component of the ongoing physicians' health study</TI>
<SO>N Engl J Med</SO>
<YR>1988</YR>
<VL>318</VL>
<PG>262-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MMWR-2001" NAME="MMWR 2001" TYPE="JOURNAL_ARTICLE">
<AU>anonymous</AU>
<TI>Morbidity and Mortality Weekly Report</TI>
<TO>Trends in screening for colorectal cancer - United States, 1997 and 1999</TO>
<YR>2001</YR>
<VL>50</VL>
<PG>162-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mukherjee-2001" NAME="Mukherjee 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mukherjee D, Nissen SE, Topol EJ</AU>
<TI>Risk of cardiovascular events associated with selective COX-2 inhibitors</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<PG>954-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newcomb-1992" NAME="Newcomb 1992" TYPE="JOURNAL_ARTICLE">
<AU>Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM</AU>
<TI>Screening sigmoidoscopy and colorectal cancer mortality</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1992</YR>
<VL>84</VL>
<PG>1572-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Niv-1994" NAME="Niv 1994" TYPE="JOURNAL_ARTICLE">
<AU>Niv Y, Fraser GM</AU>
<TI>Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy</TI>
<SO>Gastroenterology</SO>
<YR>1994</YR>
<VL>107</VL>
<PG>854-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paganini_x002d_Hill-1994" NAME="Paganini-Hill 1994" TYPE="JOURNAL_ARTICLE">
<AU>Paganini-Hill A</AU>
<TI>Aspiring and the prevention of colorectal cancer: A review of the evidence</TI>
<SO>Seminars in Surgical Oncology</SO>
<YR>1994</YR>
<VL>10</VL>
<PG>158-164</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seow_x002d_Choen-1996" NAME="Seow-Choen 1996" NOTES="&lt;p&gt;Seow-Choen F, Pappalardo G, Maiani G, al. e. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br J Surgery 1996;83:1763-6.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Seow-Choen F, Pappalardo G, Maiani G, et al</AU>
<TI>Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis</TI>
<SO>Br J Surgery</SO>
<YR>1996</YR>
<VL>83</VL>
<PG>1763-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stryker-1987" NAME="Stryker 1987" TYPE="JOURNAL_ARTICLE">
<AU>Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL</AU>
<TI>Natural history of untreated colonic polyps</TI>
<SO>Gastroenterology</SO>
<YR>1987</YR>
<VL>93</VL>
<PG>1009-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sturmer-1998" NAME="Sturmer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH</AU>
<TI>Aspirin use and colorectal cancer: Post-trial follow-up datafrom the Physicians' Health Study</TI>
<SO>Ann Intern Med</SO>
<YR>1998</YR>
<VL>128</VL>
<NO>9</NO>
<PG>713-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suleiman-2001" NAME="Suleiman 2001" TYPE="JOURNAL_ARTICLE">
<AU>Suleiman S, Rex DK, Sonnenberg A</AU>
<TI>Chemoprevention of colorectal cancer by aspirin: A cost-effectiveness analysis</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>78-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Theisen-2001" NAME="Theisen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Theisen C</AU>
<TI>Chemoprevention: What's in a name?</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2001</YR>
<VL>93</VL>
<PG>743</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorson-1994" NAME="Thorson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Thorson AG, Lynch HT, Smyrk TC</AU>
<TI>Rectal cancer in FAP patient after sulindac</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<PG>180</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trends-2001" NAME="Trends 2001" NOTES="&lt;p&gt;Trends in screening for colorectal cancer  - United States, 1997 and 1999. Morbidity and Mortality Weekly Report 2001;50:162-66.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Trends in screening for colorectal cancer - United States, 1997 and 1999</AU>
<TI>Trends in screening for colorectal cancer - United States, 1997 and 1999</TI>
<SO>Morbidity and Mortality Weekly Report</SO>
<YR>2001</YR>
<VL>50</VL>
<PG>162-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-1993" NAME="Turner 1993" TYPE="JOURNAL_ARTICLE">
<AU>Turner D, Berkel HJ</AU>
<TI>Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1993</YR>
<VL>149</VL>
<PG>595-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ukcccr-2002" NAME="ukcccr 2002" NOTES="&lt;p&gt;A multi-centre double blind randomised controlled trial of Aspirin and / or Folate supplementation for the prevention of recurrent colorectal adenomas. In: http://www.ctu.mrc.ac.uk/ukcccr/; 2002.&lt;/p&gt;" TYPE="COMPUTER_PROGRAM">
<AU>A multi-centre double blind randomised controlled trial of Aspirin and / or Folate supplementation for the prevention of recurrent colorectal adenomas</AU>
<TI>In: http://www.ctu.mrc.ac</TI>
<YR>2002</YR>
<PG>//www.ctu.mrc.ac.uk/ukcccr/; 2002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-USPTF-2002" NAME="USPTF 2002" NOTES="&lt;p&gt;U.S. Preventive Task Force. Aspirin for the primary prevention of cardiovascular events:  Recommendations and rationale. Ann Intern Med 2002;136:161-172.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>anonymous</AU>
<TI>US Preventive Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendations and rationale</TI>
<SO>Ann Intern Med</SO>
<YR>2002</YR>
<VL>136</VL>
<PG>161-172</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vainio-1997" NAME="Vainio 1997" TYPE="JOURNAL_ARTICLE">
<AU>Vainio H, Morgan G, Kleihues P</AU>
<TI>An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs</TI>
<SO>Cancer Epidemiology, Biomarkers and Prevention</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>749-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vernon-1997" NAME="Vernon 1997" TYPE="JOURNAL_ARTICLE">
<AU>Vernon SW</AU>
<TI>Participation in colorectal cancer screening: A review</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1997</YR>
<VL>89</VL>
<NO>19</NO>
<PG>1406-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winawer-1993" NAME="Winawer 1993" TYPE="JOURNAL_ARTICLE">
<AU>Winawer SJ, Zauber AG, Ho MN</AU>
<TI>Prevention of colorectal cancer by colonoscopic polypectomy</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>27</NO>
<PG>1977-81</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES>
<REFERENCE ID="REF-Baron" NAME="Baron" TYPE="JOURNAL_ARTICLE">
<AU>Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al</AU>
<TI>A randomized trial of aspirin to prevent colorectal adenomas</TI>
<SO>N Engl J Med</SO>
<YR>2003</YR>
<VL>348</VL>
<PG>891-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Canadian" NAME="Canadian" NOTES="&lt;p&gt;Canadian Cancer Statistics. Canadian Cancer Society. [available on-line:  accessed February 2003]: http://www.cancer.ca; 2002.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Canadian Cancer Statistics</AU>
<TI>Canadian Cancer Society. [available on-line: accessed February 2003]: http://www.cancer</TI>
<PG>//www.cancer.ca; 2002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cancer" NAME="Cancer" NOTES="&lt;p&gt;Cancer Facts &amp;amp; Figures. American Cancer Society. [available on-line:  accessed February 2003]. http://www.cancer.org; 2003.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cancer Facts &amp; Figures</AU>
<TI>American Cancer Society. [available on-line: accessed February 2003]. http://www.cancer</TI>
<PG>//www.cancer.org; 2003</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Common" NAME="Common" NOTES="&lt;p&gt;Common toxicity criteria [available on-line:  http://ctep.cancer.gov/reporting/ctc.html accessed:  May 12, 2003]. In: National Cancer Institute; 1999.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Common toxicity criteria [available on-line: http://ctep</AU>
<TI>cancer.gov/reporting/ctc.html accessed: May 12, 2003]</TI>
<PG>National Cancer Institute; 1999</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dannenberg" NAME="Dannenberg" TYPE="JOURNAL_ARTICLE">
<AU>Dannenberg AJ, Zakim D</AU>
<TI>Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2</TI>
<SO>Seminars in Oncology</SO>
<YR>1999</YR>
<VL>26</VL>
<PG>499-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gann" NAME="Gann" TYPE="JOURNAL_ARTICLE">
<AU>Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH</AU>
<TI>Low-dose aspirin and incidence of colorectal tumors in a randomized trial</TI>
<SO>J Natl Cancer Inst</SO>
<YR>1993</YR>
<VL>85</VL>
<PG>1220-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giardiello" NAME="Giardiello" TYPE="JOURNAL_ARTICLE">
<AU>Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al</AU>
<TI>Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis</TI>
<SO>N Engl J Med</SO>
<YR>1993</YR>
<VL>328</VL>
<PG>1313-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giardiello-FM_x002c_-1" NAME="Giardiello FM, 1" TYPE="JOURNAL_ARTICLE">
<AU>Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, et al</AU>
<TI>Primary chemoprevention of familial adenomatous polyposis with sulindac</TI>
<SO>N Engl J Med</SO>
<YR>2002</YR>
<VL>346</VL>
<PG>1054-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giovannucci" NAME="Giovannucci" TYPE="JOURNAL_ARTICLE">
<AU>Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC</AU>
<TI>Aspirin use and the risk for colorectal cancer and adenoma in male health professionals</TI>
<SO>Ann Intern Med</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>241-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giovannucci-E_x002c_-1" NAME="Giovannucci E, 1" TYPE="JOURNAL_ARTICLE">
<AU>Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al</AU>
<TI>Aspirin and the risk of colorectal cancer in women</TI>
<SO>N Engl J Med</SO>
<YR>1995</YR>
<VL>333</VL>
<PG>609-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta" NAME="Gupta" TYPE="JOURNAL_ARTICLE">
<AU>Gupta RA, Dubois RN</AU>
<TI>Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2000</YR>
<VL>910</VL>
<PG>196-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hawk" NAME="Hawk" TYPE="JOURNAL_ARTICLE">
<AU>Hawk E, Lubet R, Limburg P</AU>
<TI>Chemoprevention in hereditary colorectal cancer syndromes</TI>
<SO>Cancer</SO>
<YR>1999</YR>
<VL>86</VL>
<PG>1731-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Labayle" NAME="Labayle" TYPE="JOURNAL_ARTICLE">
<AU>Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al</AU>
<TI>Sulindac causes regression of rectal polyps in familial adenomatous polyposis</TI>
<SO>Gastroenterology</SO>
<YR>1991</YR>
<VL>101</VL>
<PG>635-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ladenheim" NAME="Ladenheim" TYPE="JOURNAL_ARTICLE">
<AU>Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, et al</AU>
<TI>Effect of sulindac on sporadic colonic polyps</TI>
<SO>Gastroenterology</SO>
<YR>1995</YR>
<VL>108</VL>
<PG>1083-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paganini_x002d_Hill" NAME="Paganini-Hill" TYPE="JOURNAL_ARTICLE">
<AU>Paganini-Hill A</AU>
<TI>Aspirin and the prevention of colorectal cancer: A review of the evidence</TI>
<SO>Semin Surg Onc</SO>
<YR>1994</YR>
<VL>10</VL>
<PG>158-164</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rexrode" NAME="Rexrode" NOTES="&lt;p&gt;Rexrode KM, Lee IM, N.R. C, Hennekens CH, Buring JE. Baseline characteristics of participants in the  Women's Health Study. Journal of  women's health &amp;amp; gender-based medicine 2000;9:19-27.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rexrode KM, Lee IM, N</AU>
<TI>R. C, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study</TI>
<SO>Journal of women's health &amp; gender-based medicine</SO>
<YR>2000</YR>
<VL>9</VL>
<PG>19-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandler" NAME="Sandler" TYPE="JOURNAL_ARTICLE">
<AU>Sandler RS HS, Baron JA, Budinger S, Paskett E, Kerkesztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R</AU>
<TI>A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer</TI>
<SO>N Engl J Med</SO>
<YR>2003</YR>
<VL>348</VL>
<PG>883-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steinbach" NAME="Steinbach" TYPE="JOURNAL_ARTICLE">
<AU>Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al</AU>
<TI>The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis</TI>
<SO>N Engl J Med</SO>
<YR>2000</YR>
<VL>342</VL>
<PG>1946-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trends" NAME="Trends" TYPE="JOURNAL_ARTICLE">
<AU>Trends in screening for colorectal cancer - United States, 1997 and 1999</AU>
<SO>MMWR</SO>
<YR>2001</YR>
<VL>50</VL>
<PG>162-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner" NAME="Turner" TYPE="JOURNAL_ARTICLE">
<AU>Turner D, Berkel HJ</AU>
<TI>Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer</TI>
<SO>Can Med Assoc J</SO>
<YR>1993</YR>
<VL>149</VL>
<PG>595-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vainio" NAME="Vainio" TYPE="JOURNAL_ARTICLE">
<AU>Vainio H, Morgan G, Kleihues P</AU>
<TI>An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs</TI>
<SO>Cancer Epidemiol Biomarkers Prev</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>749-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vernon" NAME="Vernon" TYPE="JOURNAL_ARTICLE">
<AU>Vernon SW</AU>
<TI>Participation in colorectal cancer screening: A review</TI>
<SO>J Natl Cancer Inst</SO>
<YR>1997</YR>
<VL>89</VL>
<NO>19</NO>
<PG>1406-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winawer" NAME="Winawer" TYPE="JOURNAL_ARTICLE">
<AU>Winawer SJ, Zauber AG, Ho MN</AU>
<TI>Prevention of colorectal cancer by colonoscopic polypectomy</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>27</NO>
<PG>1977-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winawer-SJ.-Nat1" NAME="Winawer SJ. Nat1" TYPE="JOURNAL_ARTICLE">
<AU>Winawer SJ</AU>
<TI>Natural history of colorectal cancer</TI>
<SO>Am J Med</SO>
<YR>1999</YR>
<VL>106</VL>
<PG>3S-6S</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Baron-2003">
<CHAR_METHODS>
<P>Multi-centred, randomized, double blind, placebo controlled trial<BR/>Recruitment: July 1994 to March 1998<BR/>1. Allocation concealment: Yes<BR/>2. Blinding of intervention: Yes<BR/>3. Intention to treat: Yes<BR/>4. % complete f/u: 97%<BR/>5. Blinding of outcome: measurement(s): Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sample size: 1,121<BR/>Incl. Criteria: age 21-80 years, &gt;=1 histologically documented adenoma removed &lt;=3 months prior to study enrollment, endoscopically clean colon<BR/>Excl. Criteria: FAP, HNPCC, CRC, any condition potentially worsened or treated by aspirin, other NSAIDs or folic acid<BR/>Country: USA, Canada<BR/>Setting: tertiary care outpatient<BR/>% female: 36%<BR/>Mean age: 53.2+/- 9.5 years<BR/>Baseline characteristics similar for each group: Yes<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 x 3 factorial design</P>
<P>Treatment <BR/>1. Aspirin 325 mg daily<BR/>2. Aspirin 80 mg daily<BR/>3. Folic acid 1mg daily<BR/>Control:<BR/>Placebo daily<BR/>Duration: 3 years</P>
<P>Outcome Monitoring: Qualifying colonoscopy, repeated at 1 and 3 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes:<BR/>1. Number of subjects with &gt;=1 adenoma</P>
<P>Secondary outcome:<BR/>1. Number of subjects that reported a serious adverse event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. 1409 eligible subjects underwent a 3 month run-in period<BR/>2. Compliance: &gt;90% reported &gt;= 50% compliance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Benamouzig-2003">
<CHAR_METHODS>
<P>Multi-centred, randomized double blind placebo-controlled trial<BR/>Recruitment: Dec. 1996 to Feb, 2000<BR/>1. Allocation concealment: Yes<BR/>2. Blinding of intervention: Yes<BR/>3. Intention to treat: Yes<BR/>4. % complete f/u: 87%<BR/>5. Blinding of outcome: measurement(s): Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sample size: 272<BR/>Incl. Criteria: age 18-75 years, &gt;=3 adenomas or &gt;=1 adenoma &gt;=6mm in diameter all histologically confirmed and removed &lt;=3 months prior to study enrollment, endoscopically clean colon<BR/>Excl. Criteria: FAP, HNPCC, CRC, any condition potentially worsened or treated by aspirin, other NSAIDs or folic acid<BR/>Country: France<BR/>Setting: outpatient setting<BR/>% female: 30%<BR/>Mean age: 58+/- 2 years<BR/>Baseline characteristics similar for each group: Yes<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment:<BR/>1. Lysine acetylsalicylate 160mg<BR/>2. Lysine acetylsalicylate 300mg</P>
<P>Control:<BR/>placebo</P>
<P>Duration: 4 years<BR/>(note: interim 1 year results published 2003)</P>
<P>Outcome Monitoring: Qualifying colonoscopy, repeated at 1 and 4 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes:<BR/>1. Number of subjects with &gt;=1 adenoma<BR/>2. size of new adenomas<BR/>3. polyp burden (sum of the diameters of the adenomas)</P>
<P>Secondary outcome:<BR/>1. Number of subjects that reported a serious adverse event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. 291 potentially eligible subjects underwent 4-week run-in period (must have &gt;=80% compliance of 300mg lysine ASA to be eligible) - 19 not randomized (5 had side-effects)<BR/>2. Compliance 87+/-12% of sachets for the intervention and 88+/-10% in the placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gann-1993">
<CHAR_METHODS>
<P>Randomized, double blind, placebo-controlled trial <BR/>Conducted: 1982 to 1988<BR/>1. Allocation concealment: Yes<BR/>2. Blinding of intervention: Yes<BR/>3. Intention to treat: Yes<BR/>4. % complete f/u: 99.7%<BR/>5. Blinding of outcome measurement(s): Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sample size: 22,071<BR/>Incl. Criteria: US male physicians age 41-84 years<BR/>Excl. Criteria: prior history of vascular disease, cancer, liver or renal disease, gout, PUD, current use of NSAID (&gt;=1/week) or vitamin A<BR/>Country: USA<BR/>Setting: population cohort <BR/>% female: 0%<BR/>Mean age: 53.2+/- 9.5 years<BR/>Baseline characteristics similar for each group: Yes<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 X 2 factorial design</P>
<P>Treatment 1: Aspirin 325 mg every other day<BR/>Treatment 2: Beta carotene 50mg every other day<BR/>Control 1 &amp; 2: Placebo every other day<BR/>Duration: 5 years</P>
<P>Outcome Monitoring: self-report, pathology reports, medical records, death certificates</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes:<BR/>1. Number of subjects with &gt;=1 adenoma<BR/>2. Number of subjects with the new diagnosis of CRC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. 33,223 eligible physicians underwent an 18 week run-in period<BR/>2. The randomized aspirin component was terminated early (5 years) due to statistically significant reduction of MIs.<BR/>3. Compliance: 85.7% for both aspirin and placebo groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Giardiello-1993">
<CHAR_METHODS>
<P>Single-centre, randomized, doubled blind, placebo-controlled trial:<BR/>Published: 1993<BR/>1. Allocation concealment: yes<BR/>2. Blinding of intervention: yes<BR/>3. Intention to treat: yes <BR/>4. % complete f/u: 91% <BR/>5. Blinding of outcome: measurement(s): yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sample size: 22<BR/>Incl. Criteria: FAP, intact colon or subtotal colectomy with IRA<BR/>Excl. Criteria: use of an NSAID or aspirin &gt;1 week within 3 months of the study, absence of the use of effective birth control in women of child bearing age, abnormal serum laboratory tests (WBC, plt liver, kidney), history of PUD or GI bleed, cancer, active bacterial infection<BR/>Country: USA<BR/>Setting: Outpatient tertiary care centre <BR/>% female: 59% <BR/>Mean age: Tx: 21.9+/-7.6 &amp; Cx:26.3+/-10.3 yrs<BR/>% intact colon: 82%<BR/>Baseline characteristics similar for each group: yes<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stratified by intact colon and subtotal colectomy with IRA</P>
<P>Treatment: Sulindac 150 mg twice daily<BR/>Control: Placebo twice daily<BR/>Duration: 9 months</P>
<P>Outcome Monitoring: Flexible sigmoidoscopy at baseline and at 3, 6, 9 and 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes:<BR/>1. Percent change from baseline in polyp number <BR/>2. Percent change from baseline in polyp size</P>
<P>Secondary outcome:<BR/>1. Number of subjects that reported a serious adverse event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. Apriori sample size calculation of 40, but recruitment stopped at 22 subjects because statistical guidelines were met<BR/>2. Outcomes assessment: total number of polyps were counted in the circumference of the colorectum from 20cm (tattooed) to the anal verge, videotaped, diameter of up to 5 polyps just beyond 20cm were measured with graduated scale <BR/>3. Study withdrawals: 2 patients in the sulindac group were withdrawn (one due to persistent diarrhea diagnosed as colitis secondary to clostridium difficile, another moved from the area)<BR/>4. Compliance: 85% with scheduled drug doses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Giardiello-2002">
<CHAR_METHODS>
<P>Single-centre, randomized, doubled blind, placebo-controlled trial<BR/>Conducted: Sept 1993 to July 2001<BR/>1. Allocation concealment: yes<BR/>2. Blinding of intervention: yes<BR/>3. Intention to treat: yes<BR/>4. % complete f/u: 93%<BR/>5. Blinding of outcome: yes measurement(s):</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sample size: 41<BR/>Incl. Criteria: age &gt;=8 years, has a disease-causing mutation of the APC gene, clean colon on endoscopy, intact colon<BR/>Excl. Criteria: use of an NSAID or aspirin &gt;1 week within 3 months of the study, absence of the use of effective birth control in women of child bearing age, abnormal serum laboratory tests (WBC, plt liver, kidney), history of PUD or GI bleed, cancer, active bacterial infection, body weight &lt;20kg<BR/>Country: USA<BR/>Setting: Outpatient tertiary care centre<BR/>% female: 66%<BR/>Age range: 8-25 years <BR/>% Intact colon: 100%<BR/>Baseline characteristics similar for each group: yes<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: Sulindac 75mg (body weight 20-44 kg) or 150mg (body weight &gt;44kg) twice daily<BR/>Control: Placebo twice daily<BR/>Duration: 4 years </P>
<P>Outcome Monitoring: Flexible sigmoidoscopy at baseline and every 4 months <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: <BR/>1. Number of subjects with at least 1 adenoma<BR/>2. Number of subjects with at least one pathologic diagnosis of tubulovillous or villous adenoma</P>
<P>Secondary outcome:<BR/>1. Number of subjects that reported a serious adverse event</P>
<P>Other outcomes:<BR/>1. Mean number of adenomas (SD)<BR/>2. Mean size of adenomas (SD)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. Compliance (mean +/-SD) : Treatment 86.9+/- 7.5% and Placebo 81.7+/10.4%<BR/>2. Outcomes assessment: total number of polyps were counted in the circumference of the colorectum from 20cm to the anal verge, videotaped, diameter of up to 5 polyps just beyond 20cm were measured with graduated scale <BR/>3. Study withdrawals: 5 subjects from the treatment group (3 for increasing polyps, 1 for persistent neutropenia, 1 unable to attend visits), 6 withdrew from the placebo (4 for increasing polyps, 2 unable to attend visits)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Labayle-1991">
<CHAR_METHODS>
<P>Multi-centre, randomized, double blind, placebo-controlled cross-over trial <BR/>Published: 1991 <BR/>Type of trial:<BR/>1. Allocation concealment: Yes<BR/>2. Blinding of intervention: Yes<BR/>3. Intention to treat: Yes<BR/>4. % complete f/u: 90%<BR/>5. Blinding of outcome measurement(s): Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sample size: 10<BR/>Incl. Criteria: FAP, age &gt;18 years, previous colectomy with IRA, rectal adenomas <BR/>Excl. Criteria: PUD, cirrhosis, abnormal serum creatinine<BR/>Country: France<BR/>Setting: Outpatient <BR/>% female: 20%<BR/>Mean age: 37 (24-52) years<BR/>% intact colon: 0%<BR/>Baseline characteristics similar for each group: yes<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cross-over design: 1 month wash-out<BR/>period prior to cross-over</P>
<P>Treatment:<BR/>Sulindac 100mg three times daily<BR/>Control:<BR/>Placebo three times daily<BR/>Duration: 4 months </P>
<P>Outcome Monitoring: Flexible rectoscopy at baseline and after each 4 month treatment period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: <BR/>1. Change in polyp burden (better/worse/same)</P>
<P>Secondary outcome: <BR/>1. Number of subjects that reported an adverse event</P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. One patient did not complete study and was excluded due to lack of compliance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ladenheim-1995">
<CHAR_METHODS>
<P>Multi-centre, randomized, double blind, placebo-controlled trial <BR/>Published: 1995<BR/>1. Allocation concealment: Yes<BR/>2. Blinding of intervention: Yes<BR/>3. Intention to treat: Yes<BR/>4. % complete f/u: 100%<BR/>5. Blinding of outcome measurement(s): Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sample size: 44<BR/>Incl. Criteria: age &gt;50 years old scheduled for routine screening flex sig, adenomas &lt;=1cm in diameter<BR/>Excl. Criteria: adenomas &gt;1cm in diameter, history of GI bleeding, PUD, cancer, long-term use of NSAIDs (except aspirin), severe lung or cardiac disease<BR/>Country: USA<BR/>Setting: Outpatient endoscopy <BR/>% female: 13.6%<BR/>Mean age: 64.4+/- 7.5 years <BR/>Baseline characteristics similar for each group: yes except Mean number of polyps was greater in the sulindac group (2.0+/-1.5) vs. placebo (1.3+/-0.9)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment : Sulindac 150 mg twice daily<BR/>Control: Placebo twice daily<BR/>Duration: 4 months</P>
<P>colonoscopy at 4 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: <BR/>1. Change in polyp burden (# patients for whom polyps either disappeared or regressed by at least 25% in diameter) </P>
<P>Secondary outcome: <BR/>1. Number of subjects that reported an adverse event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. From 162 eligible patients, 44 were enrolled <BR/>2. Compliance: 89%<BR/>3. Assessment of outcomes: polyps were photographed, adenoma diameter estimated by comparison to open biopsy forcep, adenoma location estimated by distance from anal verge<BR/>4. 4 patients (sulindac group) discontinued intervention (3 side effects, 1 urosepsis)<BR/>5. 12/44 subjects (8 sulindac, 4 placebo) were taking 80-325 mg aspirin regularly, discontinued for study duration</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sandler-2003">
<CHAR_METHODS>
<P>Multi-centred, randomized, double blind, placebo controlled trial<BR/>Conducted: May 1993 to January 2000<BR/>1. Allocation concealment: Yes<BR/>2. Blinding of intervention: Yes<BR/>3. Intention to treat: Yes<BR/>4. % complete f/u: 81%<BR/>5. Blinding of outcome: measurement(s): Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sample size: 635<BR/>Incl. Criteria: age 30-80 years, histologically documented colon or rectal cancer with a low risk of recurrent disease, within 4 months prior to study enrollment, endoscopically clean colon<BR/>Excl. Criteria: FAP, cardiovascular disease, other nonmelanoma invasive cancer within 5 years, immunsuppressive therapy within 6 months, IBD, contraindication to apsirin, current use of NSAID Country: USA<BR/>Setting: tertiary care outpatient <BR/>% female: 48%<BR/>Median age range: 60-69 years<BR/>Baseline characteristics similar for each group: Yes<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment <BR/>1. Aspirin 325 mg daily<BR/>Control:<BR/>Placebo daily<BR/>Duration: planned for 3 years terminated early (after 1 year) after planned interim analysis</P>
<P>Outcome Monitoring: Qualifying colonoscopy, repeated at 1 and 3 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes:<BR/>1. Number of subjects with &gt;=1 adenoma<BR/>2. Number of subjects &gt;=1adenoma &gt;=1cm <BR/>3. Number of subjects with tubulovillous or villous adenomas <BR/>Secondary outcome:<BR/>1. Number of subjects that reported a serious adverse event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. 719 eligible subjects underwent a 3 month run-in period<BR/>2. Compliance: &gt;90% reported &gt;= 50% compliance <BR/>3. endoscopy was performed as part of the usual follow-up for patients with CRC and was performed by each patient's own gastroenterologist or surgeon</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Steinbach-2000">
<CHAR_METHODS>
<P>Multi-centre, randomized, double blind, placebo-controlled trial <BR/>Conducted: Dec 1996 to Dec 1998<BR/>1. Allocation concealment: Yes 2. Blinding of intervention: Yes<BR/>3. Intention to treat: Yes<BR/>4. % complete f/u: 96%<BR/>5. Blinding of outcome measurement(s): Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Sample size: 77<BR/>Incl. Criteria: age 18-65 years, FAP, have not had their entire colorectum removed, &gt;= 5 adenomas &gt;= 2mm that can be visualized endoscopically <BR/>Excl. Criteria: colectomy 12 months prior or planned 8 months after enrollment, use of NSAIDs or aspirin at least 3 times a week within 6 months or at least 1 time a week within 3 months, abnormal serum lab tests (CBC, liver, kidney) <BR/>Country: USA, UK<BR/>Setting: Outpatient tertiary care centres<BR/>% female: 43%<BR/>Mean age: P40+/-11, T139+/-10,T233+/-11 years <BR/>% Intact colon: 33% <BR/>Baseline characteristics similar for each group: yes except for age<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Randomized: 2:2:1</P>
<P>Treatment 1: Celecoxib 100mg twice daily<BR/>Treatment 2:<BR/>Celecoxib 400mg twice daily<BR/>Control:<BR/>Placebo twice daily<BR/>Duration: 6 months</P>
<P>Outcome Monitoring: Endoscopy at baseline and at 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: <BR/>1. Percent change from baseline in polyp burden (sum of the polyp diameters)<BR/>2. Percent change from baseline in polyp number</P>
<P>Secondary outcome:<BR/>1. Number of subjects that reported an adverse event </P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. Testing for APC gene mutations were performed at baseline <BR/>2. 103 eligible patients: 29 had insufficient number of polyps, 2 required colectomy<BR/>3. Outcomes assessment: at baseline tattoo was placed in the rectum, colon or both near high density of polyps, video &amp; photos were taken near tattoo, appendix &amp; ileocecal valve for baseline &amp; follow-up, diameters measured with a standardized endoscopic ruler or biopsy forcep<BR/>4. Two patients were withdrawn because of noncompliance and two patients were added to Treatment 1 group.<BR/>5. Compliance: 90% of subjects that completed the study took &gt;= 80% of study drug<BR/>6. 3 subjects did not complete the study: T1: 1 subject committed suicide T2: 1 subject had an allergic reaction, 1 subject had dyspepsia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>&gt;= greater than or equal to; &gt; greater than; <BR/>mm3 cubic millimeter; CBC complete blood count; plt platelet; <BR/>mg/dl milligram per deciliter; mg milligrams; kg kilograms; <BR/>APC adenomatous polyposis coli; NSAID nonsteroidal anti-inflammatory drug; <BR/>PUD peptic ulcer disease; GI gastrointestinal; MI myocardial infarction<BR/>Flex sig flexible sigmoidoscopy;<BR/> FAP familial adenomatous polyposis; HNPCC hereditary nonpolyposis colorectal cancer;<BR/>IRA ileorectal anastomosis; IBD inflammatory bowel disease; T treatment; P placebo;</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Nugent-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>This double-blind randomized controlled trial of sulindac versus placebo for FAP patients with advanced duodenal polyposis was excluded because patients with rectal polyposis were not randomized and were analysed as a subgroup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>FAP familial adenomatous polyposis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-APACC-2001">
<CHAR_STUDY_NAME>
<P>APACC</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Incl. criteria: Adults age 18-75 years, &gt;=1 histologically confirmed colorectal adenoma, clean colon on endoscopy<BR/>Excl. criteria: CRC, FAP, IBD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) aspirin 160mg daily<BR/>2) aspirin 300mg daily<BR/>3) placebo daily<BR/>Duration: 4 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Recurrence of colorectal adenomas</P>
<P>Colonoscopy at 1 and 4 years</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>November 1996</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>robert.benamouzig@avc.ap-hop-paris.fr</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>1 year interim results published in Gastroneterology August 2003</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-CAPP1">
<CHAR_STUDY_NAME>
<P>Concerted Action Polyposis Prevention 1</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>FAP gene carriers in 14 European countries</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 x 2 factorial design<BR/>1) aspirin 100mg<BR/>2) corn starch 30g (13.2 resistant starch) <BR/>Duration: 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Incidence or progression of colorectal adenomas</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Ongoing</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>http://www.ncl.ac.uk/capp/index.html<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-CAPP2">
<CHAR_STUDY_NAME>
<P>Concerted Action Polyposis Prevention 2</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Hereditary nonpolyposis colorectal cancer (HNPCC) gene carriers in 25 centres around the world.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 x 2 factorial design<BR/>aspirin 600mg, corn starch 30g (13.2 resistant starch) <BR/>Duration: 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Incidence of colorectal adenomas<BR/>(extracolonic malignancy, proliferation, apoptosis, genotype as secondary endpoints)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>March 1999</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>http://www.ncl.ac.uk/capp/index.html</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-MDA_x002d_ID_x002d_00109">
<CHAR_STUDY_NAME>
<P>Phase II Randomized study of celecoxib with or without eflornithine for the prevention of colorectal cancer in participants with familial adenomatous polyposis of the colorectum</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Adults age 18-65 years of age with a history of FAP and no anticipated colectomy within 8 months after randomization</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) celecoxib twice daily and placebo once daily<BR/>2) oral celecoxib twice daily and oral DFMO daily<BR/>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1) % change in number of polyps 2) % change in polyp size</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>http://www.cancer.gov/search/clinical trials</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-NCI_x002d_P00_x002d_0150">
<CHAR_STUDY_NAME>
<P>PhaseIIB randomized study of eflornithine (DFMO) and sulindac in the prevention of colorectal carcinoma in patients with previously resected colorectal adenoma</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Adults age 40-80 years of age with a history of at least 1 prior resected colorectal adenoma &lt;=5years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) oral sulindac and oral DFMO daily<BR/>2) placebo daily<BR/>Duration: 3 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Recurrence of colorectal adenomas</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>http://www.cancer.gov/search/clinical trials</P>
<P/>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-ukCAP">
<CHAR_STUDY_NAME>
<P>Multi-centre, double blind, randomized controlled trial of aspirin and/or folic acid as prevention of recurrent colorectal adenomas</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Adults &lt;=75 years of age with a history of histologically confirmed colorectal adenomas, clean colon by endoscopy within 6 months of enrollment, intact colon</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 X 2 factorial design <BR/>1) aspirin 300 mg daily<BR/>2) folic acid 0.5mg daily<BR/>3) placebo 1 or 2 daily<BR/>Duration: 3 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Recurrence of colorectal adenomas</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>May 1997<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>http://www.controlled-trials.com contact: MRC Clinical Trials Unit<BR/>tel: +44 (0) 20 76704723</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>March 2003: current accrual 937, projected accrual 1,300</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-WHI-1998">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Women_x0027_s-Health-Study">
<CHAR_STUDY_NAME>
<P>The Women's Health Study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Female health professionals &gt;= 45 years of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 X 2 X2 factorial design<BR/>1) aspirin 100mg every other day<BR/>2) vitamin E 600 IU every other day<BR/>3) B-carotene 50 mg every other day<BR/>4) placebo 1, 2, or 3<BR/>Duration:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Site-specific cancer or cardiovascular disease</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>April 1993</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>I_Min Lee&lt;ilee@rics.bwh.harvard.edu&gt;</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>&lt;= less than or equal to; FAP Familial adenomatous polyposis; DFMO eflornithine;<BR/>IBD Inflammatory bowel disease</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Baron-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Benamouzig-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gann-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Giardiello-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Giardiello-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Labayle-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ladenheim-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sandler-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Steinbach-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Secondary prevention: Familial adenomatous polyposis</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>% change #CR polyp</P>
</TH>
<TH>
<P>%change CRpolyp size</P>
</TH>
<TH>
<P>Change polyp burden</P>
</TH>
</TR>
<TR>
<TD>
<P>Labayle 1991</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Treatment: <BR/>Better 9<BR/>Control: Better 2<BR/>Worse 5<BR/>Same 2</P>
</TD>
</TR>
<TR>
<TD>
<P>Giardello 1993</P>
</TD>
<TD>
<P>Treatment (n=11): - 44%<BR/>Control (n=11): - 10%<BR/>
<BR/>(get raw data)</P>
</TD>
<TD>
<P>Treatment: - 35%<BR/>Control: 0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Steinbach 2000</P>
</TD>
<TD>
<P>Treatment 1 (n=32): -11.9% +/- 30.3<BR/>Treament 2 (n=30): -28.0% +/- 24.0<BR/>Control (n=15): -4.5% +/-16.4</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Treatment 1: -14.6% +/-31.7<BR/>Treatment 2: -30.7% +/-25.7<BR/>Treatment 3: -4.9% +/-17.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>NSAID/ASA vs. control</NAME>
<DICH_OUTCOME CHI2="4.547662925197478" CI_END="0.9265809026357065" CI_START="0.7250455941624899" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8196422396943206" ESTIMABLE="YES" EVENTS_1="512" EVENTS_2="439" I2="12.042733470042657" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.033116655099194044" LOG_CI_START="-0.13963468215926056" LOG_EFFECT_SIZE="-0.08637566862922728" METHOD="MH" NO="2" P_CHI2="0.33693337941062373" P_Q="0.0" P_Z="0.0014794887307548632" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0026788158970632346" TOTALS="SUB" TOTAL_1="12164" TOTAL_2="11787" WEIGHT="300.0" Z="3.1786769681414713">
<NAME>Number of subjects that develop &gt;=1 adenoma</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1006434944109715" CI_START="0.6798273603719348" DF="0.0" EFFECT_SIZE="0.8650130412403926" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="141" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.041646670940561445" LOG_CI_START="-0.16760136075996143" LOG_EFFECT_SIZE="-0.0629773449097" NO="1" P_CHI2="1.0" P_Z="0.2380877224068756" STUDIES="1" TAU2="0.0" TOTAL_1="11037" TOTAL_2="11034" WEIGHT="100.0" Z="1.179780061602945">
<NAME>Primary prevention/sporadic colorectal neoplasia</NAME>
<DICH_DATA CI_END="1.1006434944109715" CI_START="0.6798273603719348" EFFECT_SIZE="0.8650130412403926" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="141" LOG_CI_END="0.041646670940561445" LOG_CI_START="-0.16760136075996143" LOG_EFFECT_SIZE="-0.0629773449097" ORDER="2352" O_E="0.0" SE="0.12291332961534912" STUDY_ID="STD-Gann-1993" TOTAL_1="11037" TOTAL_2="11034" VAR="0.015107686597131458" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8447400849486586E-31" CI_END="1.4678905731872798" CI_START="0.41364460938735864" DF="0.0" EFFECT_SIZE="0.7792207792207793" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="100.0" ID="CMP-001.02.02" LOG_CI_END="0.16669368144363622" LOG_CI_START="-0.38337263102131275" LOG_EFFECT_SIZE="-0.10833947478883822" NO="2" P_CHI2="0.0" P_Z="0.4400802547458783" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="20" WEIGHT="100.0" Z="0.7720577096916431">
<NAME>Primary prevention/FAP</NAME>
<DICH_DATA CI_END="1.4678905731872798" CI_START="0.41364460938735864" EFFECT_SIZE="0.7792207792207793" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.16669368144363622" LOG_CI_START="-0.38337263102131275" LOG_EFFECT_SIZE="-0.10833947478883822" ORDER="2353" O_E="0.0" SE="0.32311167481407166" STUDY_ID="STD-Giardiello-2002" TOTAL_1="21" TOTAL_2="20" VAR="0.1044011544011544" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.468662927985368" CI_END="0.9642740819428991" CI_START="0.609111827937326" DF="2.0" EFFECT_SIZE="0.7663881188306785" ESTIMABLE="YES" EVENTS_1="381" EVENTS_2="287" I2="55.24388318763458" ID="CMP-001.02.03" LOG_CI_END="-0.015799506183138662" LOG_CI_START="-0.2153029671411029" LOG_EFFECT_SIZE="-0.11555123666212078" NO="3" P_CHI2="0.1070637931738202" P_Z="0.023183364996624475" STUDIES="3" TAU2="0.023122128394901572" TOTAL_1="1106" TOTAL_2="733" WEIGHT="99.99999999999999" Z="2.2703993318144993">
<NAME>Secondary prevention: sporadic colorectal neoplasia</NAME>
<DICH_DATA CI_END="1.0151327528303404" CI_START="0.7685465351314582" EFFECT_SIZE="0.8832761515439083" ESTIMABLE="YES" EVENTS_1="300" EVENTS_2="171" LOG_CI_END="0.006522840329727382" LOG_CI_START="-0.11432983104134331" LOG_EFFECT_SIZE="-0.05390349535580794" ORDER="2354" O_E="0.0" SE="0.07098945739373833" STUDY_ID="STD-Baron-2003" TOTAL_1="721" TOTAL_2="363" VAR="0.005039503061057388" WEIGHT="68.2361881684545"/>
<DICH_DATA CI_END="1.038008550435794" CI_START="0.5194521570224641" EFFECT_SIZE="0.7342995169082126" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="46" LOG_CI_END="0.016200930961175936" LOG_CI_START="-0.2844544459854663" LOG_EFFECT_SIZE="-0.13412675751214517" ORDER="2355" O_E="0.0" SE="0.176606456686576" STUDY_ID="STD-Benamouzig-2003" TOTAL_1="126" TOTAL_2="112" VAR="0.031189840543387453" WEIGHT="15.550326470625718"/>
<DICH_DATA CI_END="0.8583052259727992" CI_START="0.4362535339560794" EFFECT_SIZE="0.6119139547710977" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="70" LOG_CI_END="-0.0663582431732693" LOG_CI_START="-0.36026104193211456" LOG_EFFECT_SIZE="-0.21330964255269194" ORDER="2356" O_E="0.0" SE="0.17263995883326297" STUDY_ID="STD-Sandler-2003" TOTAL_1="259" TOTAL_2="258" VAR="0.029804555385950733" WEIGHT="16.213485360919766"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>NSAID/ASA vs. control</NAME>
<DICH_OUTCOME CHI2="0.8291864120402209" CI_END="0.9591619835705447" CI_START="0.6010270185422897" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.759264293434449" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="108" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.018108042849912" LOG_CI_START="-0.22110600430328944" LOG_EFFECT_SIZE="-0.11960702357660076" METHOD="MH" NO="1" P_CHI2="0.842474107621721" P_Q="0.0" P_Z="0.020908446530830502" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1981" TOTAL_2="1263" WEIGHT="200.0" Z="2.3096336222273948">
<NAME>Number of subjects that develop higher risk adenomas</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.050781741933765126" CI_END="0.9998361752293933" CI_START="0.4473643480027676" DF="1.0" EFFECT_SIZE="0.6687982196754702" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="41" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-7.11540224284197E-5" LOG_CI_START="-0.3493386292751864" LOG_EFFECT_SIZE="-0.17470489164880737" NO="1" P_CHI2="0.8217085264861625" P_Z="0.04990672669022791" STUDIES="3" TAU2="0.0" TOTAL_1="1001" TOTAL_2="641" WEIGHT="100.00000000000001" Z="1.9607625663216184">
<NAME>&gt;= pathologic diagnosis of tubulovillous or villous adenomas</NAME>
<DICH_DATA CI_END="1.014255894151694" CI_START="0.42433046361030125" EFFECT_SIZE="0.6560332871012483" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="33" LOG_CI_END="0.006147540201967221" LOG_CI_START="-0.3722957881652021" LOG_EFFECT_SIZE="-0.18307412398161743" ORDER="2357" O_E="0.0" SE="0.22229948440756325" STUDY_ID="STD-Baron-2003" TOTAL_1="721" TOTAL_2="363" VAR="0.04941706076786846" WEIGHT="85.17547866036938"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2358" O_E="0.0" SE="0.0" STUDY_ID="STD-Giardiello-2002" TOTAL_1="21" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.122972672775823" CI_START="0.26291659953935914" EFFECT_SIZE="0.747104247104247" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.32694440389795865" LOG_CI_START="-0.5801819933506018" LOG_EFFECT_SIZE="-0.12661879472632165" ORDER="2359" O_E="0.0" SE="0.5328505360918901" STUDY_ID="STD-Sandler-2003" TOTAL_1="259" TOTAL_2="258" VAR="0.2839296938134147" WEIGHT="14.82452133963063"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.20153294913262626" CI_END="1.0795171535572923" CI_START="0.6078139459709603" DF="1.0" EFFECT_SIZE="0.8100281358366491" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="67" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.033229547676353166" LOG_CI_START="-0.21622933948353748" LOG_EFFECT_SIZE="-0.09149989590359214" NO="2" P_CHI2="0.6534863390830228" P_Z="0.15048965667215397" STUDIES="2" TAU2="0.0" TOTAL_1="980" TOTAL_2="622" WEIGHT="100.0" Z="1.4378040614384604">
<NAME>&gt;=1 adenoma &gt;=1cm in diameter</NAME>
<DICH_DATA CI_END="1.0721502574040311" CI_START="0.5874202858317626" EFFECT_SIZE="0.7936011659888573" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="59" LOG_CI_END="0.030255654189350344" LOG_CI_START="-0.2310510597324015" LOG_EFFECT_SIZE="-0.10039770277152557" ORDER="2360" O_E="0.0" SE="0.1534928572467321" STUDY_ID="STD-Baron-2003" TOTAL_1="721" TOTAL_2="363" VAR="0.02356005722576568" WEIGHT="91.1374397796909"/>
<DICH_DATA CI_END="2.62407492178193" CI_START="0.38108667999499424" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4189762307234218" LOG_CI_START="-0.4189762307234219" LOG_EFFECT_SIZE="0.0" ORDER="2361" O_E="0.0" SE="0.49221742378545713" STUDY_ID="STD-Sandler-2003" TOTAL_1="259" TOTAL_2="259" VAR="0.2422779922779923" WEIGHT="8.862560220309106"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Secondary prevention: Sporadic colorectal neoplasia</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Number of subjects where adenomas regressed or disappeared</NAME>
<GROUP_LABEL_1>Sulindac</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Sulindac vs. control</NAME>
<DICH_DATA CI_END="6.137977284793343" CI_START="0.45255589079152186" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7880252768773026" LOG_CI_START="-0.34432777764458977" LOG_EFFECT_SIZE="0.22184874961635637" ORDER="2362" O_E="0.0" SE="0.6651497894641796" STUDY_ID="STD-Ladenheim-1995" TOTAL_1="22" TOTAL_2="22" VAR="0.4424242424242424" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3490461830452989" CI_END="-0.03754398026142012" CI_START="-0.12504804293456123" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.08129601159799067" ESTIMABLE="YES" EVENTS_1="381" EVENTS_2="287" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="3" P_CHI2="0.5093993430222102" P_Q="0.0" P_Z="2.707117628787693E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1106" TOTAL_2="733" WEIGHT="100.0" Z="3.6418253039060318">
<NAME>Number of subjects with &gt;=1 adenoma</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3490461830452989" CI_END="-0.03754398026142012" CI_START="-0.12504804293456123" DF="2.0" EFFECT_SIZE="-0.08129601159799067" ESTIMABLE="YES" EVENTS_1="381" EVENTS_2="287" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.5093993430222102" P_Z="2.707117628787693E-4" STUDIES="3" TAU2="0.0" TOTAL_1="1106" TOTAL_2="733" WEIGHT="100.0" Z="3.6418253039060318">
<NAME>Secondary prevention: sporadic colorectal neoplasia</NAME>
<DICH_DATA CI_END="0.0077140959212835675" CI_START="-0.11768532504520467" EFFECT_SIZE="-0.05498561456196055" ESTIMABLE="YES" EVENTS_1="300" EVENTS_2="171" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2363" O_E="0.0" SE="0.03199023603383094" STUDY_ID="STD-Baron-2003" TOTAL_1="721" TOTAL_2="363" VAR="0.0010233752015002158" WEIGHT="48.692869876737554"/>
<DICH_DATA CI_END="0.012211259155398405" CI_START="-0.23046522740936665" EFFECT_SIZE="-0.10912698412698413" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="46" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2364" O_E="0.0" SE="0.06190840456226906" STUDY_ID="STD-Benamouzig-2003" TOTAL_1="126" TOTAL_2="112" VAR="0.0038326505554455766" WEIGHT="13.001726820862439"/>
<DICH_DATA CI_END="-0.034602999882878877" CI_START="-0.17598632698551772" EFFECT_SIZE="-0.1052946634341983" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="70" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2365" O_E="0.0" SE="0.03606783803627324" STUDY_ID="STD-Sandler-2003" TOTAL_1="259" TOTAL_2="258" VAR="0.0013008889406108386" WEIGHT="38.305403302400016"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>NSAID/Aspirin vs. control</NAME>
<DICH_OUTCOME CHI2="3.918106725886012" CI_END="1.3182351733205506" CI_START="0.6473477776535548" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9237730294145889" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.1199928953600112" LOG_CI_START="-0.18886233859374144" LOG_EFFECT_SIZE="-0.03443472161686513" METHOD="MH" NO="1" P_CHI2="0.5612659689166553" P_Q="0.0" P_Z="0.6620834279495239" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1343" TOTAL_2="911" WEIGHT="100.0" Z="0.43703850067714517">
<NAME>Number of subjects with an adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.918106725886012" CI_END="1.3182351733205506" CI_START="0.6473477776535548" DF="5.0" EFFECT_SIZE="0.9237730294145889" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="25" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.1199928953600112" LOG_CI_START="-0.18886233859374144" LOG_EFFECT_SIZE="-0.03443472161686513" NO="1" P_CHI2="0.5612659689166553" P_Z="0.6620834279495239" STUDIES="8" TAU2="0.0" TOTAL_1="1343" TOTAL_2="911" WEIGHT="100.0" Z="0.43703850067714517">
<NAME>All Interventions</NAME>
<DICH_DATA CI_END="3.831652092045058" CI_START="0.5047220032290499" EFFECT_SIZE="1.3906542056074767" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.5833860689439794" LOG_CI_START="-0.2969477618946789" LOG_EFFECT_SIZE="0.14321915352465026" ORDER="2366" O_E="0.0" SE="0.5171124499573709" STUDY_ID="STD-Baron-2003" TOTAL_1="749" TOTAL_2="372" VAR="0.2674052859009145" WEIGHT="12.308783899053788"/>
<DICH_DATA CI_END="2.9837845668872607" CI_START="0.03310410252142502" EFFECT_SIZE="0.3142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4747674633081284" LOG_CI_START="-1.4801181816922298" LOG_EFFECT_SIZE="-0.5026753591920505" ORDER="2367" O_E="0.0" SE="1.148309504713219" STUDY_ID="STD-Benamouzig-2003" TOTAL_1="140" TOTAL_2="132" VAR="1.3186147186147186" WEIGHT="2.496130091037429"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2368" O_E="0.0" SE="0.0" STUDY_ID="STD-Giardiello-1993" TOTAL_1="22" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.218244504526753" CI_START="0.06379335213776025" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1528459783163107" LOG_CI_START="-1.1952245764561868" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="2369" O_E="0.0" SE="1.3792682670100667" STUDY_ID="STD-Giardiello-2002" TOTAL_1="21" TOTAL_2="20" VAR="1.9023809523809523" WEIGHT="1.7301654926157715"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2370" O_E="0.0" SE="0.0" STUDY_ID="STD-Labayle-1991" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="128.01989359781342" CI_START="0.3827530130116973" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1072774619013144" LOG_CI_START="-0.41708138187280086" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="2371" O_E="0.0" SE="1.4828208806107213" STUDY_ID="STD-Ladenheim-1995" TOTAL_1="22" TOTAL_2="22" VAR="2.1987577639751548" WEIGHT="1.4969515658097947"/>
<DICH_DATA CI_END="3.0771140791210603" CI_START="0.32703340653863056" EFFECT_SIZE="1.003154574132492" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4881435973246063" LOG_CI_START="-0.48540788179124406" LOG_EFFECT_SIZE="0.001367857766681175" ORDER="2372" O_E="0.0" SE="0.5718689579901945" STUDY_ID="STD-Sandler-2003" TOTAL_1="317" TOTAL_2="318" VAR="0.3270341051127909" WEIGHT="10.064497329671067"/>
<DICH_DATA CI_END="1.2879067703893616" CI_START="0.5567379187258632" EFFECT_SIZE="0.8467741935483871" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="10" LOG_CI_END="0.10988442624515414" LOG_CI_START="-0.2543491984297481" LOG_EFFECT_SIZE="-0.07223238609229699" ORDER="2373" O_E="0.0" SE="0.2139526341195579" STUDY_ID="STD-Steinbach-2000" TOTAL_1="62" TOTAL_2="15" VAR="0.045775729646697405" WEIGHT="71.90347162181214"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20594705555869905" CI_END="2.447047465121341" CI_START="0.5771331067744665" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1883905527940142" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.3886423933977057" LOG_CI_START="-0.23872401202461957" LOG_EFFECT_SIZE="0.0749591906865431" METHOD="MH" NO="2" P_CHI2="0.9021509436594012" P_Q="0.0" P_Z="0.6395256894915258" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1087" TOTAL_2="710" WEIGHT="100.00000000000003" Z="0.4683620697126559">
<NAME>Number of subjects with a serious adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.20594705555869905" CI_END="2.447047465121341" CI_START="0.5771331067744665" DF="2.0" EFFECT_SIZE="1.1883905527940142" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.3886423933977057" LOG_CI_START="-0.23872401202461957" LOG_EFFECT_SIZE="0.0749591906865431" NO="1" P_CHI2="0.9021509436594012" P_Z="0.6395256894915258" STUDIES="3" TAU2="0.0" TOTAL_1="1087" TOTAL_2="710" WEIGHT="100.00000000000003" Z="0.4683620697126559">
<NAME>All Interventions</NAME>
<DICH_DATA CI_END="3.831652092045058" CI_START="0.5047220032290499" EFFECT_SIZE="1.3906542056074767" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.5833860689439794" LOG_CI_START="-0.2969477618946789" LOG_EFFECT_SIZE="0.14321915352465026" ORDER="2374" O_E="0.0" SE="0.5171124499573709" STUDY_ID="STD-Baron-2003" TOTAL_1="749" TOTAL_2="372" VAR="0.2674052859009145" WEIGHT="48.78287273936657"/>
<DICH_DATA CI_END="14.218244504526753" CI_START="0.06379335213776025" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1528459783163107" LOG_CI_START="-1.1952245764561868" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="2375" O_E="0.0" SE="1.3792682670100667" STUDY_ID="STD-Giardiello-2002" TOTAL_1="21" TOTAL_2="20" VAR="1.9023809523809523" WEIGHT="7.479225029518568"/>
<DICH_DATA CI_END="3.0771140791210603" CI_START="0.32703340653863056" EFFECT_SIZE="1.003154574132492" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4881435973246063" LOG_CI_START="-0.48540788179124406" LOG_EFFECT_SIZE="0.001367857766681175" ORDER="2376" O_E="0.0" SE="0.5718689579901945" STUDY_ID="STD-Sandler-2003" TOTAL_1="317" TOTAL_2="318" VAR="0.3270341051127909" WEIGHT="43.73790223111488"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>NSAID/Aspirin vs. control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="68" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="11758" TOTAL_2="11397" WEIGHT="0.0" Z="0.0">
<NAME>Number of subjects diagnosed with CRC</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="55" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11037" TOTAL_2="11034" WEIGHT="0.0" Z="0.0">
<NAME>Primary prevention/sporadic colorectal neoplasia</NAME>
<DICH_DATA CI_END="1.6425613029676869" CI_START="0.7983585982676633" EFFECT_SIZE="1.1451431960265883" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="55" LOG_CI_END="0.21552158708647187" LOG_CI_START="-0.09780199302593282" LOG_EFFECT_SIZE="0.05885979703026954" ORDER="2377" O_E="0.0" SE="0.18404782193476188" STUDY_ID="STD-Gann-1993" TOTAL_1="11037" TOTAL_2="11034" VAR="0.03387360075892982" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="721" TOTAL_2="363" WEIGHT="0.0" Z="0.0">
<NAME>Secondary prevention/sporadic colorectal neoplasia</NAME>
<DICH_DATA CI_END="21.46719920516847" CI_START="0.2951938756244503" EFFECT_SIZE="2.517337031900139" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3317753863512074" LOG_CI_START="-0.5298926570458027" LOG_EFFECT_SIZE="0.40094136465270236" ORDER="2378" O_E="0.0" SE="1.0935530240968427" STUDY_ID="STD-Baron-2003" TOTAL_1="721" TOTAL_2="363" VAR="1.1958582165113498" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA18AAAHACAIAAADSi0WBAAAwNElEQVR42u3d2ZKkOrJA0fzz+nTd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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-04" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>